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Introduction 
Endometriosis is known to be a devastating disease, not only because of its association with 
abdominal pain and infertility, but also the poor outcome of treatment given especially to 
those with associated fertility problem. However, detection and treatment given at early 
stage of disease may give better prognosis compared to those in advanced stage. Making 
an early diagnosis of endometriosis is therefore important for these patients. Direct 
visualization of the endometriotic lesions, with or without being confirmed histologically is at 
present the gold standard tool to make the diagnosis of endometriosis. Clinical manifestation 
alone could not confirmed the diagnosis. Tumour marker eg. CA 125 is not specific to 
endometriosis. Ultrasonography studies could not be of much value unless there is presence 
of endometrioma. Many patients are reluctant to undergo surgery in our centre. Therefore, 
we are to find a non-invasive way to make the diagnosis of endometriosis so that early 
treatment with better outcome could be offered to the patients. 
 
Objective 
This study was performed to create a scoring system name Cli-Endomet, which suggestive 
of endometriosis, by evaluating the association between the medical history, clinical 
examination, ultrasound findings and biochemical marker ( CA 125 ). 
 
 
Methodology 
This was a cross sectional study, performed over 18 months duration from November 1st, 
2011 until April 31st 2013. 176 patients with pelvic pain, which include dysmenorrhea, 
dyspareunia, ovulation pain, dyschezia or any chronic non-specific pelvic pain were recruited 
into the study. Detailed history and a thorough clinical examination were performed on each 
patient. A transvaginal ultrasound scan was performed and 2 mls of blood was taken from 
each patients either during menstruation or late luteal phase to determine the level of serum 
CA 125. All patients were then been subjected to either laparoscopy or laparotomy operation 
and/or tissue biopsy was taken for histopathology examination whenever was possible. In 
the presence of endometriosis, the staging of disease was determined using revised 
American Society of Reproductive Medicine (rASRM) scoring system. The clinical criterias 
which were strongly associated with diagnosis of endometriosis were extracted from 
statistical model, and were transformed for development of the clinical criteria scoring 
system, the Cli-Endomet. 
 
 
 
 
 
Results 
Among 176 patients recruited, 103 of them (58.5%) were confirmed to have endometriosis. 
The clinical manifestations and CA 125 level were analyzed via simple logistic regression 
then followed by multiple logistic regression, to determine the association between clinical 
presentation, CA 125 and endometriosis. The ROC (Receiver Operating Characteristic) 
curve of CA 125 was plotted and the cutoff points of  CA 125  level in association with 
endometriosis were 50 to 200 U/mL with  p value < 0.001. The clinical parameters which 
were statistically significant were dysmenorrhea ( especially severe type, p < 0.015 ), 
ultrasonography finding of ovarian mass (if present) with ground-glass appearance or thick 
with sediments content ( p < 0.001 ) and CA 125 level ( p < 0.001 ). From this analysis 
results, a scoring system Cli-Endomet was then developed.  
 
Conclusion  
CliEndomet scoring system, which takes into consideration of several significant clinical 
parameters, can be used as an alternative tool that suggestive of endometriosis. However, 
the accuracy of CliEndomet is not fully validated yet. Should it proven to be accurate, it may 
avoid patient from unnecessary diagnostic surgical procedure and further medical treatment 
may be instituted accordingly. 
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ABSTRAK 
Objektif 
Kajian ini telah dilaksanakan untuk merumuskan satu system pemarkahan yang 
dinamakan Cli-Endomet, yang mencadangkan penyakit endometriosis, dengan menilai 
keberkesanan dalam persatuan antara  sejarah perubatan, pemeriksaan klinikal, 
penemuan ciri ultrasound dan penanda biokimia (CA 125) dari pemeriksaan darah 
pesakit. 
 
Kaedah Kajian 
Ini adalah satu kajian keratan rentas,  yang dilaksanakan dalam tempoh 18 bulan, 
mulai 1hb November 2011 hingga 31hb April 2013. Sebanyak 176 pesakit dengan 
simptoms seperti sakit senggugut, sakit semasa melakukan hubungan seksual, sakit 
semasa membuang air besar, sakit pada bahagian bawah abdomen sama ada semasa 
ovulasi atau masa yang tidak spesifik, telah dipilih untuk menyertai kajian ini. Sejarah 
perubatan yang terperinci dan pemeriksaan klinikal yang teliti telah dijalankan ke atas 
setiap pesakit. Imbasan ultrasound melalui faraj telah dilaksanakan dan 2 mls darah 
telah diambil dari setiap pesakit sama ada semasa haid atau fasa luteal lewat untuk 
menentukan tahap serum CA 125. Semua pesakit kemudiannya telah menjalani 
pembedahan secara laparoscopy atau laparotomy dan tisu biopsy diambil, sekiranya 
ada, untuk pemeriksaan histopatologi. Pesakit-pesakit yang mempunyai endometriosis 
telah dikategorikan kepada 4 peringkat menggunakan klasifikasi “revised American 
Society for Reproductive Medicine (rASRM) scoring system”.  Kriteria klinikal yang 
berkait rapat dengan diagnosa endometriosis ini dikumpulkan dari model statistic, dan 
telah digunakan untuk penciptaan system pemarkahan dengan kriteria klinikal, dengan 
nama Cli-Endomet. 
 
xiii 
 
Keputusan 
Antara 176 pesakit , 103 daripada mereka ( 58.5 %) telah disahkan mempunyai 
endometriosis. Manifestasi klinikal dan tahap CA 125 dianalisis melalui ‘simple logistic 
regression’ kemudian diikuti oleh ‘multiple logistic regression’ , untuk menentukan 
hubungan antara persembahan klinikal, CA 125 dan endometriosis. “ROC” ( Receiver 
Operating Characteristic ) lengkung CA 125 diplot dan tahap CA 125 yang berkait rapat 
dengan endometriosis adalah 50-200 U / mL dengan nilai p < 0.001 . Parameter 
klinikal yang secara statistik penting adalah sakit senggugut (kesakitan yang teruk, p < 
0.015 ) , imbasan jisim ovari dengan ultrasound (jika ada) dengan penampilan “ground-
glass” atau tebal dengan sedimen kandungan (p <0.001 ) dan keputusan darah CA 
125 ( p < 0.001) . Dari keputusan analisis ini, sistem pemarkahan Cli- Endomet telah 
dirumuskan. 
 
Kesimpulan 
Sistem pemarkahan CliEndomet, yang mengambil kira beberapa parameter klinikal 
yang ketara, boleh digunakan sebagai alat alternatif yang menandakan endometriosis. 
Walau bagaimanapun, ketepatan CliEndomet ini tidak disahkan sepenuhnya lagi. 
Sekiranya ia terbukti tepat, ia boleh mengelakkan pesakit daripada prosedur 
pembedahan dignostik yang tidak diperlukan dan rawatan perubatan selanjutnya boleh 
dimulakan dengan sewajarnya. 
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ABSTRACT 
Objective 
This study was performed to create a scoring system name Cli-Endomet, which 
suggestive of endometriosis, by evaluating the association between the medical history, 
clinical examination, ultrasound findings and biochemical marker ( CA 125 ). 
 
Methodology 
This was a cross sectional study, performed over 18 months duration from November 
1st, 2011 until April 31st 2013. 176 patients with pelvic pain, which include 
dysmenorrhea, dyspareunia, ovulation pain, dyschezia or any chronic non-specific 
pelvic pain were recruited into the study. Detailed history and a thorough clinical 
examination were performed on each patient. A transvaginal ultrasound scan was 
performed and 2 mls of blood was taken from each patients either during menstruation 
or late luteal phase to determine the level of serum CA 125. All patients were then 
been subjected to either laparoscopy or laparotomy operation and/or tissue biopsy was 
taken for histopathology examination whenever was possible. In the presence of 
endometriosis, the staging of disease was determined using revised American Society 
of Reproductive Medicine (rASRM) scoring system. The clinical criterias which were 
strongly associated with diagnosis of endometriosis were extracted from statistical 
model, and were transformed for development of the clinical criteria scoring system, 
the Cli-Endomet. 
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Results 
Among 176 patients recruited, 103 of them (58.5%) were confirmed to have 
endometriosis. The clinical manifestations and CA 125 level were analyzed via simple 
logistic regression then followed by multiple logistic regression, to determine the 
association between clinical presentation, CA 125 and endometriosis. The ROC 
(Receiver Operating Characteristic) curve of CA 125 was plotted and the cutoff points 
of  CA 125  level in association with endometriosis were 50 to 200 U/mL with  p value < 
0.001. The clinical parameters which were statistically significant were dysmenorrhea 
( especially severe type, p < 0.015 ), ultrasonography finding of ovarian mass (if 
present) with ground-glass appearance or thick with sediments content ( p < 0.001 ) 
and CA 125 level ( p < 0.001 ). From this analysis results, a scoring system Cli-
Endomet was then developed.  
 
Conclusion  
CliEndomet scoring system, which takes into consideration of several significant clinical 
parameters, can be used as an alternative tool that suggestive of endometriosis. 
However, the accuracy of CliEndomet is not fully validated yet. Should it proven to be 
accurate, it may avoid patient from unnecessary diagnostic surgical procedure and 
further medical treatment may be instituted accordingly. 
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1.0 INTRODUCTION 
 
Endometriosis is a common gynecological disorder affecting women of reproductive 
age. It was first identified in the mid-nineteenth century (Von Rokitansky, 1860). It is 
defined as a disease characterized by the presence of tissue that is biologically and 
morphologically similar to normal endometrium, contains endometrial glands and 
stroma, in ectopic locations outside the uterine cavity.  This ectopic endometrial tissue 
responds to hormones and drugs in a generally similar manner to eutopic endometrium 
undergoing cyclical changes. Cyclical bleeding from the endometriotic deposits 
appears to contribute to the induction of a local inflammatory reaction and fibrous 
adhesions; in the case of deep implants in the ovary, it can lead to formation of  
endometriomas (Pratibha, 2006). 
 
Women with endometriosis may be asymptomatic, subfertile or suffer varying degree of 
pelvic pain. Incidence of endometriosis ranges from 1% to 10% of general population, 
up to 30 – 40% in women with infertility, the incidence is higher in women with pelvic 
pain with an incidence of 82% (Othman, 2008; Hooghe, 2002; Mounsey, 2006). 
However, the diagnosis of this condition remains difficult. The ‘gold standard’ of 
diagnosing endometriosis is by direct visualization of the lesions with or without 
histology confirmation. Unfortunately, this invasive procedure has potential 
complications, with positive predictive value differs if lesions are typical focal (76%) or 
atypical adhesion-forming (25-50%) (Walter, 2001). 
 
Besides, the use of laparoscopy is limited by available finding, the surgeon’s 
experience, and human error, including missing non-specific lesions (Razvan et al, 
2011). 
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The predictive value of any one or set of symptoms or clinical manifestations of 
endometriosis remain uncertain. A normal physical examination also does not rule out 
the diagnosis of endometriosis with poor sensitivity (38-79%), specificity (32-80%) and 
positive predictive value (54-62%) (Eskenazi B, 2004 ). Ultrasound has limited value in 
diagnosis but it is useful to exclude ovarian endometrioma (Moore J, 2002). 
 
Thus, development of a simple blood test as a marker for screening patients at risk for 
endometriosis would reduce the number of unnecessary interventions and would 
therefore be very useful (Stefan et al, 2010). Increasingly efforts are made to use less 
invasive tests with a low cost and high negative predictive value (Patrelli, 2011 ). 
 
CA -125 is the cell surface antigen expressed by derivatives of coelomic and mullerian 
epithelia. The antigenic determinant of high-molecular-weight glycoprotein is detected 
by monoclonal antibody CA-125 (Robert et al., 2006 ). 
 
Barbieri et al. reported higher concentrations of CA 125 in the glandular epithelium of 
endometriotic lesions than in the endometrium (Barbieri et al, 1986 ). Indeed, Koninckx 
et al (1996) after evaluating CA-125 in peritoneum and in the blood, concluded that 
superficial disease causes its elevation in peritoneal fluid, whereas deep disease 
causes its elevation in blood. The performance of CA-125 for the diagnosis of 
endometriosis has been assessed in a meta-analysis, with estimated sensitivity of 28% 
and specificity of 90% (corresponding likelihood ratio of raised level is 2.8 ). This test 
performance for moderate to severe endometriosis is better, with sensitivity of 47%, 
and specificity of 89% (corresponding likelihood ratio of raised level is 4.3 ) (Chapron, 
2004). Despite poor sensitivity, several reports have demonstrated that serum CA-125 
level may predict the response to medical and surgical treatment.  
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We are now trying to find a clinical diagnostic criteria, named Cli - Endomet to assist in 
diagnosis of endometriosis based on the clinical manifestations, radiological imaging 
and laboratory marker, comparing with direct visual inspection of pelvis at laparoscopy 
or laparotomy, with or without histology confirmation, to improve diagnostic sensitivity 
and specificity, hoping that surgical intervention can be avoided and medical therapy 
can be instituted according to the Cli-Endomet. According to Tommaso et al., a 
nonsurgical diagnosis of endometriosis is useful even if the management is surgical 
rather than medical (Tommaso et al., 2003 ). If it is proven that Cli-Endomet is a 
reliable tool that highly suggestive of endometriosis, then the high possibility of 
endometriosis could be made without surgical procedure and the appropriate treatment 
could be started accordingly. 
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2.0 LITERATURE  REVIEW 
2.1  PATHOPHYSIOLOGY 
2.1.1 Aetiology 
The definitive cause of endometriosis remains unknown, it is often called the disease of 
theories as several theories with supporting evidence have been put forward: 
a. Retrograde menstruation 
b. Coelomic metaplasia 
c. Induction theory 
d. Genetic and immunological factors 
e. Defects in embryogenesis theory 
2.1.1(a)  Retrograde Menstruation  (Implantation Metastasis theory) 
The most widely accepted theory, proposed in the 1920s by Sampson, that claim the 
adhesion and growth of endometrial fragments deposited into the peritoneal cavity via 
retrograde menstruation (Sampson, 1927). The refluxed endometrial fragments adhere 
to and invade the peritoneal mesothelium and develop a blood supply, which leads to 
continued implant survival and growth (Giudice, 2004). This theory is supported by the 
fact that endometriosis is commonly found in young girls with obstructive abnormalities 
of genital tract, which is often relieved by surgical correction of the obstruction 
(Sanfilippo, 1986). It has been suggested that enhanced angiogenesis could be a 
factor in the development of this lesions as the endometriotic areas are frequently 
found to have increased vascularity. This is further supported by the presence of potent 
angiogenic growth factor (vascular endothelial growth factor, VEGF), which is found in 
the peritoneal fluid of patients with endometriosis together with transforming growth 
factor-β and intracellular adhesion molecule-1 (1 CAM). Their levels decrease 
significantly after treatment with gonadotrophin-releasing hormone (GnRH) analogues 
(Pratibha et al., 2006) 
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2.1.1(b)  Coelomic  Metaplasia 
First described in 1919 by Meyer, postulates the possibility of coelomic membrane 
metaplasia to endometrium-like tissue following chronic irritation and stimulation by 
oestrogen (Pratibha et al., 2006). Because the ovary and the progenitor of 
endometrium, the mullerian ducts are both derived from coelomic epithelium, 
metaplasia may explain the development of ovarian endometriosis (Chapron, 2004). 
This theory also explain the peritoneal endometriosis due to proliferative and 
differentiation potential of the peritoneal mesothelium. This theory is attractive in 
instance of endometriosis in the absence of menstruation, such as in premenarchal 
and post-menopausal women, and in males treated with estrogen and orchidectomy for 
prostatic carcinoma (Dictor, 1988; Pinkert, 1979). However, the absence of 
endometriosis in other tissues derived from coelomic epithelium argues against this 
theory. 
 
2.1.1(c)  Induction theory 
This theory was introduced by Levander and Norman in 1955, was based on the 
assumption that endometriosis results from the differentiation of mesenchymal cells, 
induced by substances (hormonal or biologic factors), which may be exogenous or 
released by degenerating endometrium (Bontis, 1997; Pratibha, 2006). In vitro studies 
have demonstrated the potential for ovarian surface epithelium, in response to 
estrogens, to undergo transformation to form endometriotic lesions (Matsuura, 1999). 
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2.1.1(d)  Genetic and Immunological factors 
Endometriosis is more prevalent in certain families, and it has been shown that there is 
seven fold higher risk of developing endometriosis of a severe grade in women with 
first-degree relatives with the disorder (Robert, 2006). There is also high incidence 
found in monozygotic twins compared with dizygotic twins, suggesting some genetic 
link in endometriosis. 
 
2.1.1(e)  Defects in Embryogenesis Theory 
This theory postulates that endometriosis is caused by small defects of embryogenesis 
(Knapp, 1999; Benagiano and Brosens, 2006), suggested that the endometrial tissue, 
misplaced outside the uterine cavity during the earlier steps of organogenesis and 
displaying identical molecular phenotype to the endometrium present in uterus. This 
ectopic endometrium would remain quiescent and asymptomatic until puberty, where 
the hormonal changes cause its regrowth  and  subsequently  the  onset  of  symptoms  
of  endometriosis.  
 
2.1.2  Hormonal Dependence 
Oestrogen has been definitely established as having a causative role in the 
development of endometriosis (Gurates, 2003). Estrogen mainly produced by ovaries, 
minimal amount by peripheral tissues, through aromatization of ovarian and adrenal 
androgens.  
The endometriotic implants express aromatase and 17β-hydroxysteroid 
dehydrogenase type 1, which convert androstenedione to estrone and of estrone to 
estradiol, respectively, but these implants are deficient in 17β-hydroxysteroid 
dehydrogenase type 2, which inactivate estrogen (Kitawaki, 1997; Zeitoun, 1998).  
Thus, implants will be exposed to an estrogenic environment. 
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Normal endometrium does not express aromatase and has elevated 17β-
hydroxysteroid dehydrogenase type 2 in response to progesterone (Satyaswaroop, 
1982), the progesterone inhibit the estrogen effects during luteal phase of menstrual 
cycle. Prostaglandin E2 (PGE2) is the most potent inducer of aromatase activity in 
endometrial stromal cells, the aromatase activity produces estradiol, which further 
augments PGE2  production by stimulating the cyclooxygenase type 2 (COX-2) enzyme 
in uterine endothelial cells ( Bulun, 2002; Gurates, 2003 ). This causes a positive 
feedback loop and potentiates the estrogenic effects on proliferation of  endometriosis.  
2.1.3  Role  of  Immune System 
In retrograde menstruation, the menstrual tissue and endometrium is usually cleared by 
immune cells e.g. macrophages, natural killer (NK) cells, and lymphocytes. Thus, 
immune system dysfunction is one likely mechanism for the genesis of endometriosis 
in retrograde menstruation (Seli, 2003). One study showed the macrophages in women 
with endometriosis have a stimulatory effect on endometriotic tissue, enhanced the 
proliferation of endometrial cells, whereas the monocytes from women without 
endometrioses had the opposite effect (Braun, 1994), this shows there is impaired 
function of macrophages allows endometriotic tissue proliferation. Besides, Wilson et al 
(1994) & Ho et al (2001) had demonstrated the decrease in NK cell cytotoxicity against 
endometrium.  
 
The cellular immunity may be disordered and T lymphocytes are implicated in women 
with endometriosis. Humoral immunity, including endometrial antibodies (IgG), are 
detected in serum of women with endometriosis (Odukoya, 1995), suggest that 
endometriosis may be, in part, an autoimmune disease.  This may explain lower 
pregnancy and in vitro fertilization (IVF) implantation rates in affected women (Dmowski, 
1995).  
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Cytokines, especially interleukins  IL-1β, IL-6, IL-8) and TNF-α are elevated in affected 
individuals and stimulate proliferation of  endometrial stromal cells (Arici, 1996; Arici, 
1998; Ryan, 1995). 
2.2  CLASSIFICATION 
The gold standard of endometriosis diagnosis is visualization of endometriotic lesions 
by laparoscopy, with or without histological confirmation. The initial classification 
created by the American Fertility Society (AFS) in 1979, which has been subsequently 
renamed the American Society for Reproductive Medicine (ASRM), was revised for the 
third time in 1996 but still with limitations. In this system, endometriosis is classified as 
stage I (minimal), stage II (mild), stage III (moderate), stage IV (severe). This 
classification system (r-ASRM) did not provide any prognostic information with respect 
to subsequent fertility or severity of pelvic pain (Guzick, 1982, 1997).  
 
2.3  DIAGNOSIS OF ENDOMETRIOSIS 
2.3.1 Clinical Manifestation 
The main presenting symptoms of endometriosis include pelvic pain and infertility. The 
pain include dysmenorrhea, dyspareunia, chronic pelvic pain, ovulation pain, dyschezia 
(pain on defecation), and non-cyclical pelvic pain. There may be other associated 
urinary and bowel symptoms in cases of  the bladder and bowel involvement.  
The underlying cause of this pain is unclear, but proinflammatory cytokines and 
prostaglandins released by endometriotic implants into the peritoneal fluid may be one 
source (Giudice, 2004). Recent data suggest that endometriosis pain may result from 
neuronal invasion of endometriotic implants that subsequently develop a sensory and 
sympathetic nerve supply, which may undergo central sensitization (Berkley, 2005). 
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Dysmenorrhea in endometriosis patient is most often related to rectovaginal septum or 
uterosacral ligament disease (Murphy, 2002 ; Vercellini, 1996). 
 
Painful defecation typically reflects rectosigmoid involvement with endometriotic 
implants, may be chronic or cyclic, and associated with constipation, diarrhea or cyclic 
hematochezia ( Azzena, 1998; Remorgida, 2007). 
 
Infertility may result from adhesions which are caused by endometriosis and impair 
normal oocyte pick-up and transport by the fallopian tube. Beyond mechanical 
impairment of ovulation and fertilization, perturbations in ovarian and immune function 
as well as implantation appear to be involved in the pathogenesis of infertility in women 
with endometriosis (Chapron, 2004). Some researchers have suggested that 
folliculogenesis is impaired in women with endometriosis (Pellicer, 1995). Other 
investigations found that oocyte number may be decreased or apoptosis with 
decreased oocyte competence in women with endometriosis cause infertility, but well-
designed studies are lacking (Garrido, 2002 ; Harlow. 1996 ). 
 
Abnormality in endometrial development supports the possibility that implantation 
defects may be responsible for subfertility associated with endometriosis. Deficient 
αvβ3 integrin expression in the peri-implantation endometrium of women with 
endometriosis has been demonstrated, and this may be the cause of decreased uterine 
receptivity (Lessey, 1994). 
 
Sperm function may be affected as studies showed increased phagocytosis of 
spermatozoa by macrophages from women with endometriosis (Haney, 1981; Muscato, 
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1982 ) and sperm binding to the zona pellucida appears to be adversely affected (Qiao, 
1998). 
2.3.2 Physical Examination 
2.3.2.(a) Visual inspection  
Rarely, endometriosis may develop spontaneously within perineum or perianal area 
(Watanabe, 2003), or other sites such as an episiotomy or surgical scar (e.g.  
Pfannenstiel scar).  
 
2.3.2.(b) Speculum examination 
14% of patients with deeply infiltrating endometriosis have positive findings on 
speculum examination (Chapron, 2002). Occasionally, bluish or red powder burn 
lesions may be seen on posterior fornix or cervix, with tender or contact bleeding. 
 
2.3.2.(c) Bimanual examination 
Uterosacral ligament nodularity, thickened and tenderness may indicate active disease 
of endometriosis. Ovarian endometrioma may be felt as cystic adnexal mass, which 
may mobile or adherent. The pouch of Douglas may be obliterated with retroverted, 
fixed and tender uterus ( Chapron, 2004). 
 
2.3.3 Laboratory Testing 
2.3.3. (a)  Serum CA125 
CA 125 is an antigenic determinant on a glycoprotein, found in several adult tissues 
such as epithelium of fallopian tube, endometrium, endocervix, pleura and peritoneum 
(Chapron, 2004). Marked increase are observed during pregnancy and peritoneal 
irritation by infection or surgery, and also found in over 80% of cases of epithelial 
ovarian carcinoma. Elevated serum CA 125 has been shown to positively correlate with 
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the severity of endometriosis (Hornstein, 1995). Elevated plasma CA125 post-
treatment can be used as an argument that treatment is not complete or the condition 
has recurred. However, it has poor sensitivity in detecting mild endometriosis. A study 
by Mol.et.al (1998) revealed a sensitivity of 28% and specificity of 90% (corresponding 
likelihood ratio of a raised level is 2.8). It appeared to be a better test in detecting stage 
III and IV endometriosis, for a specificity of 89% and sensitivity was 47% (RCOG 
greentop guideline, 2006). 
 
2.3.3. (b)  Other serum markers 
Serum CA 19-9, placental protein 14, interleukin-6, tumor necrosis factor -α have been 
studied, with limited diagnostic accuracy and rarely used (Bedaiwy, 2004).  
 
2.3.4 Diagnostic Laparoscopy 
The gold standard for detecting endometriosis disease is direct visualization via 
laparoscopy or laparotomy with or without histopathology confirmation (Gerard A. et. al, 
2012).  The findings are variable, include discrete endometriotic lesions, endometrioma 
and adhesion formation. The endometriotic lesions can be red polypoid lesions, clear 
lesions, red flame or powder burn lesions, blue black or brown lesions, yellow, white 
lesions or peritoneal windows ( Pratibha, 2006). The endometriosis commonly located 
at ovaries, ligaments around the uterus, space between the rectum and vagina or 
cervix (Women’s Health, 2007). Latest guideline by ESHRE on endometriosis (ESHRE, 
2013) stated that the combination of laparoscopy and the histological verification of 
endometrial glands and/or stroma is considered for the diagnosis of endometriosis. The 
GDG (Guideline Development Group) recommends that endometriosis diagnosed by a 
positive laparoscopy with histology, even though negative histology does not exclude it. 
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Endometriomas are cystic endometrial lesions contained within the ovary. 
Laparoscopic visualization of ovarian endometriomas has a sensitivity and specificity of  
97% and 95%, respectively ( Vercellini, 1991 ). 
 
2.3.5 Diagnostic Imaging 
Transvaginal ultrasound (TVS) has limited value in diagnosing peritoneal endometriosis 
but it is a useful tool both to make and to exclude the diagnosis of an ovarian 
endometrioma (RCOG, 2006). The sensitivity is range from 64% to 90% and specificity 
is range from 22% to 100%  of TVS to diagnose endometriomas (Moore, 2002). At 
present, there is insufficient evidence to indicate that magnetic resonance imaging 
(MRI) is a useful test to diagnose or exclude endometriosis compared to laparoscopy 
(RCOG, 2006).  
 
2.4 TREATMENT 
Endometriosis is difficult to treat, since with the most treatment modalities there is 
eventual recurrence in up to 60%. It is thought that the only definitive treatment is total 
abdominal hysterectomy with bilateral salpingo-oophorectomy, but even after radical 
surgery the recurrence rate is 5-10% (Pratibha, 2006). Treatment for endometriosis 
depends on symptoms and its severity, location of endometriotic lesions, goals for 
treatment and desire to conserve future fertility (Olive, 2001). The current treatments 
are medical, surgical or a combination of both. 
 
2.4.1 Medical  Treatment 
2.4.1 (a) Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
Endometriotic tissue has been shown to express cyclooxygenase-2 (COX-2) at greater 
levels than eutopic endometrium (Ota, 2001). Therefore, NSAIDs, are often first line 
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therapy, aimed at lowering the prostaglandin levels may play a role in alleviating 
endometriosis-associated pain.  
 
2.4.1 (b) Combined Oral Contraceptives (COC) 
The COC is usually drug of choice in women who do not wish to conceive. These drugs 
act by inhibiting gonadotropin release, decreasing menstrual flow, and decidualizing 
implants (Chapron, 2004). It can be used continuously  in long term for controlling 
symptoms. 
 
2.4.1 (c) Progesterone 
Progesterone are known to antagonize estrogenic effects on the endometrium, causing 
initial decidualization and subsequent endometrial atrophy, produce a state of  
pseudopregnancy. It can be administered in multiple ways, such as oral progestins, 
depot medroxyprogesterone acetate (DMPA), a levonogestrel-releasing intrauterine 
device (MIRENA), and selective progesterone-receptor modulators (SPRM) (Chapron, 
2004). The SPRM suppress estrogen-dependent endometrial growth and induce 
reversible amenorrhoea without the adverse side-effects of estrogen-deficiency 
(Pratibha, 2006). 
 
2.4.1. (d) Danazol 
Danazol is an isoxazol derivative of 17α-ethinyl testosterone, has both androgenic and 
anabolic properties. It suppress the hypothalamic-pituitary axis with an interference of 
the pulsatile gonadotrophin surge with no change in basal gonadotrophin levels 
(Robert.S, 2006). Danazol is highly effective in treatment of endometriosis, with 
symptomatic improvement in 55-93% of cases. But the recurrence rate is up to 40% 
within 36 months of completion of  the danazol treatment ( Pratibha, 2006). 
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2.4.1. (e) Gonadotrophin-releasing hormone agonists (GnRH agonists) 
GnRH agonists induce pituitary gonadotrophin desensitization via the downregulation 
of the GnRH receptors, with an eventual state of  hypogonadotrophic-hypogonadism-
pseudomenopause (Pratibha, 2006).  GnRH agonist therapy is limited due to possible 
loss of up to 6% of bone mineral density in the first 6 months and the loss may not 
always be entirely reversible (RCOG, 2006). 
Add- back therapy (low-dose estrogen, low-dose progestin or tibolone) may be added 
to GnRH agonist therapy to counteract the bone loss (Carr, 1995). In a meta-analysis, 
bone mineral density was significantly higher in women taking add-back therapy with 
GnRH agonist compared with a GnRH alone, for 6 months duration. Besides, 
hypoestrogenic adverse effects were significantly less severe in women who received 
‘add-back’ (RCOG, 2006). 
 
2.4.2 Surgical Treatment 
2.4.2 (a) Conservative surgery 
The principles of surgical treatment of endometriosis include ablation, vaporization or 
excision of peritoneal implants, excision or ablation of endometriomas, excision of deep 
infiltrating nodular endometriosis and restoration of pelvic anatomy by adhesiolysis 
(Francesca,2010). It is reported at 5- year follow up, the disease recurred about 20% 
for surgery compared to about 50%  for medical treatment, and 30% will not experience 
any improvement in symptoms after surgery (Saad.A, 2010).  
 
Laparoscopic uterosacral nerve ablation (LUNA) can be performed during diagnostic 
laparoscopy. The results seem beneficial in reducing the dysmenorrhea but adequate 
randomized trials have not been performed.  
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2.4.2 (b) Radical surgery 
Radical surgery is reserved for patients with severe symptoms and no desired potential 
for fertility, especially when other forms of treatment have failed (Robert, 2006). This 
includes total abdominal hysterectomy with or without bilateral oophorectomy along 
with resection of any endometriotic lesions as completely as possible. Pre-operative 
trial of GnRH agonist may be helpful and hormone replacement therapy may be 
commenced post-operatively in young patients (Francesca, 2010), but there is 
insufficient evidence of any effect on outcome measures such as pain relief to justify its 
usage (RCOG, 2006). 
 
Endometriomas are often treated surgically, as ovarian masses often prompt surgical 
investigations. One randomized controlled trial has compared cystectomy with surgical 
drainage and bipolar coagulation of endometrioma’s inner lining (Beretta, 1998). 
Cystectomy lead to lower rates of pelvic pain compared with drainage and coagulation 
(10% versus 53%), cumulative pregnancy rates were also higher following cystectomy 
during 24-month surveillance (67% versus 24%).  
 
In some patients, transection of presacral nerves lying within interiliac triangle may 
provide relief of chronic pelvic pain. Presacral neurectomy may be performed 
laparoscopically, but it is technically challenging, thus it is used in a limited manner and 
not recommended routinely for management of endometriosis (Chapron, 2004). 
2.4.3 Treatment of  Endometriosis-related Infertility 
30-40% of women with endometriosis suffer from infertility. Medical treatment of 
endometriosis does not improve fertility. In minimal-mild cases, ablation of 
endometriotic lesions plus adhesiolysis can improve fertility, compared with diagnostic 
laparoscopy alone (RCOG, 2006). The role of surgery in improving pregnancy rates for 
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moderate-severe disease is uncertain. Post-operative hormonal treatment has no 
beneficial effect on pregnancy rates after surgery (RCOG, 2006). Alternatively, patients 
with endometriosis and infertility are candidates for fertility treatments such as 
controlled ovarian hyperstimulation, intrauterine insemination, and in vitro fertilization 
(Chapron, 2004).  
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3.0  HYPOTHESIS  AND  OBJECTIVES 
 
3.1  RESEARCH  HYPOTHESIS 
The   new  CliEndomet  could   be   used   to  diagnose   endometriosis. 
 
3.2  OBJECTIVE 
3.2.1  General objective : 
- To create a scoring system, i.e.  CliEndomet as a reliable tool to suggest 
endometriosis 
 
3.2.2  Specific  objectives : 
- To determine the correlation between the clinical manifestation (including 
medical history, physical examination and ultrasonographic features) and 
biochemical marker (Ca125) with the diagnosis of  endometriosis.  
 
- To identify the prognostic factors among the clinical manifestation, and 
biochemical marker towards the diagnosis of endometriosis. 
 
- To formulate a scoring system which highly suggestive of endometriosis. 
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4.0  METHODOLOGY 
4.1  STUDY  DESIGN, SETTING  AND  DURATION 
This was a cross sectional study with a goal to develop a clinical criteria tool 
“ CliEndomet”. This study was conducted in Hospital Raja Perempuan Zainab II, Kota 
Bharu and Hospital Universiti Sains Malaysia (HUSM) for 18 months duration, from 1st 
November 2011 until 31st April 2013.  This study consisted of 176 patients who 
presented with pelvic pain. 
4.2  REFERENCE POPULATION 
Patient with pelvic pain (dysmenorrhea, dyspareunia, ovulation pain, dyschezia and 
any chronic non-specific pelvic pain) in Kelantan. 
4.3  SOURCE  POPULATION  AND  SAMPLING  FRAME 
Patient with pelvic pain (dysmenorrhea, dyspareunia, ovulation pain, dyschezia  and 
any chronic non-specific pelvic pain ), presented at gynaecology clinic, Hospital Raja 
Perempuan Zainab II and Hospital Universiti Sains Malaysia, Kelantan. 
4.4  SAMPLE SIZE CALCULATION 
The sample size was calculated using the two proportion formula as below:  
n = p1(1 - p1)  +  p0 (1 - p0)  x   (zα + zβ)²  
      ____________________ 
                   (p1 – p0) ² 
 
P0 = estimated proportion of endometriosis in women without chronic pelvic pain 
35.0% (Chapron et.al., 2005 : Endometriosis is detected in 2-50% of women with no 
symptoms ) 
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P1 = estimated proportion of endometriosis in women with chronic pelvic pain 62% 
(Robert Z. et.al., 2003 : Endometriosis is diagnosed among women with pelvic pain 
with prevalence ranging from 15-70% ) 
Zα and Zβ = study reference ( in Pocock’s table) 
n = 66 + 13 (20% drop out) for each group 
A minimum of 158 patients are required to be recruited. However, in this study 176  
patients were recruited. 
4.5  INCLUSION AND EXCLUSION CRITERIAS 
Patients with the below criteria were included into the study : 
 
a. Age between 18 to 45 years old 
 
b. Regular menstrual cycle 
 
c. Have at least one of  the symptoms suggestive of endometriosis: 
 
i. Dysmenorrhoea 
 
ii. Deep dyspareunia 
 
iii. Ovulation pain 
 
iv. Pelvic pain 
 
v. Dyschezia 
However, those with any of the below criteria were excluded: 
 
a) Patients with known case of endometriosis prior to recruitment. 
 
b) Patients who had pelvic pain which were already confirmed to be 
 
 caused by other disorders such as pelvic inflammatory disease,  
 
varices or genital malformation 
 
c) Patients with psychiatric problems 
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4.6  ETHICS AND CONSENT 
This study was approved by the Medical Research and Ethics Committee of Ministry of  
Health and Human Medical Research and Ethics Committee of  USM. Written consents 
were obtained from patients after they fulfilled the inclusion and exclusion criteria. 
4.7  SAMPLING METHOD 
All patients who came to seek treatment at Gynaecology clinic of  Hospital Raja 
Perempuan Zainab II and Hospital Universiti Sains Malaysia, fulfilling the inclusion and 
exclusion criteria were recruited into the study. 
4.8  STUDY METHOD 
Each patient was evaluated for the pain intensity, menstrual pattern, parity and 
subfertility. The  dysmenorrhea  and non-menstrual pain ( including pelvic pain and 
ovulation pain) were evaluated using a modified version of Andersch and Milsom’s 
multidimensional verbal rating scale ( Konincky PR, 1996 ), which defines pain 
according to the limitation of  ability to work ( unaffected = 0, rarely affected = 1, 
moderately affected=2, clearly affected =3), co-existing of systemic symptoms 
(absent=0, present=1), the systemic symptoms including nausea, vomiting, 
fatigue/weariness, intestinal complaints such as periodic bloating, 
diarrhea/constipation, referred pain to back or legs (ESHRE, 2013), and the need for 
analgesia ( no=0, yes=1) and rank the total sum in three groups (1-2=mild, 3-
4=moderate, 5=severe). The severity of deep dyspareunia and dyschezia was 
evaluated using a 10-point linear analogue scale, in which scoring 0 indicates no pain 
and scoring 10 indicates unbearable pain. 
On physical examination, which was performed by a trained gynaecologist, body mass 
index (BMI) of each patient was calculated. It was followed by abdominal examination 
to look for any abdominal mass. If  any abdominal mass was noted, further details of 
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the mass were evaluated (size, site, margin, surface, consistency, mobility and 
tenderness). For patients who have had sexual exposure, pelvic examination was 
done, to look for size, position and mobility of  uterus, presence of  vaginal nodule 
including size, site and tenderness, any adnexal mass or thickening and tenderness of  
uterosacral ligaments, any obliteration of  Pouch of  Douglas (POD). All  the information 
was documented in the research forms  and  was  entered  into  a  computerized  
database.  
An ultrasound scanning of the pelvis ( either trans-abdominal or trans-vaginal) was 
performed to all patients. It was done by a same examiner who was blinded to patient’s 
clinical data. The ultrasound machine which was used in this study was CAPASEE II 
(Toshiba Otawara, Japan) connected to a 3.75MHz transducer. Findings regarding the 
uterus size, endometrial thickness, flexion and presence of any abnormality were 
documented. If  there was any ovarian or adnexal mass present, the details including 
the size, site, locule, presence of septum or papillary projection, the nature and content 
of the mass were recorded. 
As suggested by Koninckx et al (1996), blood sample for Ca-125 was collected via 
venepuncture technique, it was performed during the late luteal phase or during 
menstruating  as the test is more reliable when it is done during this time than in 
follicular phase. 2mls of blood was taken and was transported to Immunology Lab of  
HRPZ  II  or  HUSM  respectively in plain container for analysis.  
The concentration of  Ca-125 in serum samples were determined by means of a one-
step-sandwich radioimmunoassay (Fujirebio America Inc.). 100μL of undiluted serum 
samples were incubated overnight in duplicate with polystyrene beads coated with anti-
CA 125 mAbs (capture antibody). Unbound molecules in the serum was removed by 
washing the beads. The bound radioactivity was proportional to the Ca-125 
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concentration in serum samples.  Serum Ca-125 was expressed in u/mL serum and 
was calculated by comparison to a standard curve that ranges from 0 to 500U/mL. The  
sensitivity of this method was established at 0.4U/mL. Interassay and intra-assay 
variations were less than 5% (Daniele Gagne et al, 2003).  This Ca-125 level was 
unknown to the surgeon performing the operation later, and the decision to perform 
operation (either laparoscopy or laparotomy) did not depend on the serum Ca-125 
concentration. 
A laparoscopy or laparotomy operation was performed on each patient to confirm the 
presence or absence of endometriosis. The diagnosis of endometriosis required the 
presence of typical bluish or blackish lesions, with or without tissue biopsy was taken 
for histopathology examination. The staging of endometriosis was determined 
according to the revised classification of the American Society for Reproductive 
Medicine (R-ASRM). 
The clinical criteria which were strongly associated with the diagnosis of endometriosis 
from this study subjects were extracted from statistical model, and were transformed 
for development of the clinical criteria scoring system, the Cli-Endomet. 
4.9  STATISTICAL ANALYSIS 
All the data collected were entered, cleaned and analyzed using SPSS version 19.0. 
The mean and standard deviations for numerical variables and frequency and 
proportion for categorical variables were reported along with histogram or bar chart. 
For univariable analysis the simple logistic regression was used. 
For multivariable analysis, multiple logistic regression was used for analysis to adjust 
for confounding variables, to look for association between the clinical manifestation, 
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biochemical marker (Ca 125), surgical staging and histopathology results. Level of 
significance was set at 5% and results were presented with 95% confidence intervals. 
Area under curve (AUR) was used to determine the sensitivity and specificity of each 
variable in production of criteria for Cli-Endomet . Generalized likelihood ratio test 
statistics were used and P value of  < 0.05 was considered to indicate statistical 
significance 
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4.10  FLOW CHART OF STUDY 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Patients attended Gynae clinics, HUSM and HRPZ II with symptoms suggestive of 
endometriosis 
Diagnosis of non-
endometriosis 
Clinical diagnosis of 
endometriosis with 
histopathological confirmation  
Histopathology sampling not 
obtained or inadequate samples 
Histopathology  positive 
for endometriosis 
Negative visual appearance for 
endometriosis 
Positive visual appearance for 
endometriosis 
Operation and/or tissue specimen for diagnosis of endometriosis 
Blood investigation taken during menstruation or late luteal phase 
Ultrasound examination 
Clinical assessment 
 History taking 
 Abdominal and pelvic examination 
Consent 
Exclusion criteria Inclusion criteria 
Clinical diagnosis of endometriosis 
without histopathological 
confirmation 
Clinical diagnosis of Endometriosis 
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5.0  RESULTS  
A total of 176 patients were recruited into the study, out of which 103 patients (58.5 %) 
were diagnosed to have endometriosis during operation (Figure 1). Out of these 103 
patients who were noted to have endometriosis intraoperatively, 92 patients (89.3%) 
were confirmed to have endometriosis with tissue diagnosis.  
 
Figure 1: Distribution of endometriosis diagnosis among the participants 
5.1 Demographic data 
5.1.1 Age 
The age of the patients recruited ranges from 23 to 43 years old. The mean age was 
35.41± 6.90 years. 
5.1.2 Parity 
Endometriosis is one of the causes for infertility. Therefore, the parity of the subjects 
was looked into. All subjects are married. 66 (37.5%) of them remained nulliparous. 39 
subjects (22.2%) have one or two children (Para 1 or Para 2), while the rest (n=71, 
40.3%) have more than 2 children, as shown in Table 1.  
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Among the 66 subjects who were nulliparous, 48 (27.3%) of them were confirmed to 
have endometriosis. 22 subjects (12.5%) in the Para 1 and 2 and 33 (18.8%) of the 
more than Para 2 were confirmed to have endometriosis (Figure 2). 
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Figure 2: Parity distribution with endometriosis 
5.1.3 Body mass index 
There is a wide range of body mass index (BMI) of the subjects in this study. Their BMI 
ranges from less than 18kg/m2 to more than 40kg/m2. Majority of them have normal 
and overweight BMI. The distribution of the subjects’ BMI is as shown in Figure 3. 
 
Figure 3: Distribution of the BMI of the subjects 
The mean BMI of the subjects was 25.10±4.79kg/m2, which was overweight. 
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Table 1: Demographic data of subjects 
Variables Frequency 
(n) 
Percentage 
(%) 
Mean Standard 
deviation 
(SD) 
P value 
Age (years)   35.41 6.90  
Parity: 
 Nulliparous 
 Para 1-2 
 Para 3-5 
 Para 6 and 
above 
 
66 
39 
56 
15 
 
37.5 
22.2 
31.8 
8.5 
   
BMI (kg/m2): 
 ≤ 18.5 
 18.5- 24.9 
 25.0- 29.9 
 30.0- 34.9 
 35.0- 39.9 
 ≥ 40.0 
 
10 
87 
48 
26 
4 
1 
 
5.7 
49.4 
27.3 
14.7 
2.3 
0.6 
25.10 4.79  
Mean BMI (kg/m2): 
 With 
endometriosis 
 No 
endometriosis 
   
24.96 
 
25.19 
 
4.82 
 
4.78 
 
History of sub-fertility: 
 Present 
• With 
endometriosis 
• Without 
endometriosis 
 Absent 
• With 
endometriosis 
• Without 
endometriosis 
 
106 
 
63 
 
 
43 
 
70 
40 
30 
 
60.2 
 
59.4 
 
 
40.6 
 
39.8 
57.1 
42.9 
 
   
Duration of sub-fertility 
(years, n= 106): 
 2-4  
 5-7 
 ≥ 8 
              
 
32 
23 
51                            
 
 
30.2 
21.7 
48.1 
4.12 5.41  
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Mean duration of 
subfertility (years): 
 With 
endometriosis 
 Without 
endometriosis 
   
 
4.69 
 
3.38 
 
 
5.62 
 
5.05 
 
 
5.1.4 History of subfertility 
As stated above, endometriosis is one of the causes for infertility. Therefore, this 
parameter is looked into in this study. Only those with involuntary subfertility are 
considered as being sub-fertile in this study. 
Among the 176 subjects, 106 subjects (60.2%) have history of subfertility (Table 1). 
The mean duration of subfertility was 4.12 ± 5.41 years. 
Out of those with history of subfertility, 63 subjects (59.4%) were confirmed to have 
endometriosis, while the rest (n=43, 40.6%) did not have endometriosis. The mean 
duration of subfertility for those with endometriosis was 4.69 ± 5.62 years as compared 
to 3.38 ± 5.05 years in those without endometriosis. Seventy subjects (39.8%) have no 
history of sub-fertility. Forty of them (57.1%) were confirmed to have endometriosis and 
another 30 did not have one (Table 1).  
When comparing the frequency of those subjects who were diagnosed to have 
endometriosis (n = 103, 100% ), 63 subjects (61.2%) had history of subfertility, and 40 
subjects (38.8%) did not have subfertility, which was statistically significant (p value < 
0.05). 
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5.2 Clinical features 
5.2.1 Clinical manifestation 
As shown in Table 2, 169 (96.0%) subjects presented with dysmenorrhea, while 7 of 
them (4.0%) did not have such symptom. The distribution of the severity of 
dysmenorrhoea was noted to be equal among all the 169 subjects. 60 subjects (35.5%) 
experienced mild dysmenorrhoea, 73 (43.2%) moderate and the rest (n=36, 21.3%) 
have severe dysmenorrhoea, which caused them to take work leave and regular 
analgesia. 
Only 26 subjects (14.8%) of these subjects experienced deep dyspareunia, 3 subjects 
(1.7%) were certain they have ovulation pain and 4 subjects (2.2%) experienced 
dyschezia.   
The relationship of each clinical presentation (together with the demographic data) with 
the presence of endometriosis was looked into. 
Among the 169 subjects who had dysmenorrhoea, 100 subjects (56.8%) were noted to 
have endometriosis. Even though its presence indicated a high possibility to be caused 
by endometriosis, it was not shown to be statistically significant (crude OR 2.90 95% CI 
0.52-16.27; p value 0.227). However, when comparing the severity of dysmenorrhoea 
experienced by the subjects, the presence of severe dysmenorrhea was significantly 
associated with the presence of endometriosis (crude OR 14.67, 95% CI 2.18-98.78, p 
value 0.006). 
 
30 
 
Table 2: The frequency and distribution of clinical features 
Variables Frequency (N) Percentage (%) 
Dysmenorrhoea (n=176) 
 Present 
 Absent 
 
169 
7 
 
96.0 
4.0 
Severity of 
dysmenorrhoea (n=169) 
 Mild 
 Moderate 
 Severe 
 
 
60 
73 
36 
 
 
35.5 
43.2 
21.3 
Deep dyspareunia 
(n=176) 
 Present 
 Absent 
 
 
26 
150 
 
 
14.8 
85.2 
Ovulation pain (n=176) 
 Present 
 Absent 
 
3 
173 
 
1.7 
98.3 
Dyschezia (n=176) 
 Present 
 Absent 
 
4 
172 
 
2.3 
97.7 
 
On the other hand, 19 out of the 26 subjects (73.1%) who experienced deep 
dyspareunia were found to have endometriosis.  Similarly, the presence of deep 
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dyspareunia was associated with the presence of endometriosis but not statistically 
significant (crude OR 1.61, 95% CI 0.68-3.79, p value 0.277).  
Two of the three subjects (66.7%) who were certain to have ovulation pain and two 
subjects with dyschezia (50.0%) were diagnosed to have endometriosis. The same 
analysis on those clinical presentations and their association with endometriosis was 
found. 
5.2.2 Physical Examination findings 
Out of the 176 subjects, 97 subjects (55.1%) were found to have abdominal mass 
during abdominal examination. 91 subjects (93.8%) in whom the abdominal masses 
were noted had regular and well defined margin, while the rest (n=6, 6.2%) had 
irregular margin. In consistence with that, 94 masses (96.9%) had smooth surface. 87 
masses (89.7%) were found to have cystic consistency while the rest (n=10, 10.3%) 
were firm in consistency. None of the masses was hard in consistency. The mobility of 
the masses was rather equally distributed. 49 masses (50.4%) were found to be mobile 
and 45 masses (46.4%) had restricted mobility. Three masses (3.2%) were found to be 
fixed. Most of these masses were non-tender (n=92, 94.8%). 
Only five subjects (2.8%) were found to have bluish vaginal nodule, which represent 
the endometriotic nodule. 
Majority of the subjects (n=160, 90.9%) had anteverted uterus. The uteruses of most of 
the subjects regardless of their position were found to be mobile (n=111, 63.1%). Only 
65 subjects had either restricted mobility or fixed uterus (n= 65, 36.9%). 
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In consistent with the small percentage of the presence of deep dyspareunia in the 
subjects, 27 subjects (15.3%) were found to have thickened uterosacral ligaments. 
However, only eight of them had tender uterosacral ligaments. 
48 subjects (27.3%) were noted to have obliterated POD. Table 4 shows the summary 
of the distribution of the clinical findings.  
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Table 3: Clinical presentation in relation with endometriosis  
Variable b Crude OR (95% CI) Wald statistic (df) p value 
Age (year) -0.03 0.97 (0.93, 1.02) 1.49 (1) 0.222‡ 
Parity -0.23 0.80 (0.69, 0.92) 10.14 (1) 0.001† 
BMI -0.01 0.99 (0.93,1.05) 0.09 (1) 0.752 
History of subfertility 0.79 2.20 (1.19,4.06) 6.41(1) 0.011‡ 
Duration of subfertility 
(years) 
0.05 1.05 (0.99, 1.11) 2.59 (1) 0.108‡ 
Dysmenorrhoea 
 Absent 
 Present 
 
 
1.06 
 
 
2.90 (0.52, 16.27) 
 
1.00 
1.46 (2) 
 
 
0.227‡ 
Severity of dysmenorrhoea  
 No pain 
 Mild 
 Moderate 
 Severe 
 
 
-0.90 
0.62 
2.68 
 
 
0.91 (0.91,4.46) 
1.85 (0.39,8.86) 
14.67 (2.18,98.78) 
 
1.00 
0.01 (1) 
0.59 (1) 
7,62 (1) 
 
 
0.912 
0.492 
0.006† 
Deep Dyspareunia 
 Absent 
 Present 
 
 
0.48 
 
 
1.61 (0.68,3.79) 
 
1.00 
1.18 (1) 
 
 
0.277 
Deep Dyspareunia pain 
score 
0.28 
 
1.33 (1.00, 1.76) 
 
3.87 (1) 
 
0.049† 
 
Ovulation pain 
 Absent 
 Present 
 
 
0.77 
 
 
2.16 (0.22, 21.19) 
 
1.00 
0.44 (1) 
 
 
0.509 
Dyschezia 
 Absent 
 Present 
 
 
-0.35 
 
 
0.70 (0.09,5.11) 
 
1.00 
0.12 (1) 
 
 
0.728 
Pelvic pain 
 Absent 
 Present  
 
 
0.23 
 
 
1.26 (0.65,2.43) 
 
1.00 
0.48 (1) 
 
 
0.490 
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Table 4: Distribution of physical examination findings  
Variables 
 
Endometriosis 
N (percentage) 
 
No Endometriosis 
N (percentage) 
Total 
N (percentage) 
Abdominal mass 
( n = 176 ) 
 
   
• Present 
 
55 (31.2%) 42 (23.9%) 97 (55.1%) 
• Absent 
 
48 (27.3%) 31 (17.6%) 79 (44.9%) 
Margin of the mass 
(n = 97 ) 
 
   
• Regular 
 
50 (51.6%) 41 (42.2%) 91 (93.8%) 
• Irregular 
 
5 (5.2%) 1 (1.0%) 6 (6.2%) 
Surface of the mass 
( n = 97 ) 
 
   
• Smooth 
 
55 (56.7%) 39 (40.2%) 94 (96.9%) 
• Irregular 
 
0 (0.0%) 3 (3.1%) 3 (3.1%) 
Consistency of the mass 
 ( n =97 ) 
 
   
• Cystic 
 
53 (54.6%) 34 (35.1%) 87 (89.7%) 
• Firm 
 
2 (2.1%) 8 (8.2%) 10 (10.3%) 
• Hard 
 
0 (0.0%) 0 (0.0%) 0 (0.0%) 
Mobility of the mass 
( n = 97 ) 
 
   
• Mobile 
 
23 (23.6%) 26 (26.8%) 49 (50.4%) 
• Restricted mobility 
 
30 (30.9%) 15 (15.5%) 45 (46.4%) 
• Fixed 
 
2 (2.1%) 1 (1.1%) 3 (3.2%) 
Mass tenderness 
( n = 97 ) 
 
   
• Tender 
 
2 (2.1%) 3 (3.1%) 5 (5.2%) 
• Non – tender 53 (54.6%) 39 (40.2%) 92 (94.8%) 
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Presence of vaginal 
nodule 
 ( n = 176 ) 
 
   
• Present 
 
3 (1.7%) 2 (1.1%) 5 (2.8%) 
• Absent 
 
100 (56.8%) 71 (40.4%) 171 (97.2%) 
Position of uterus 
( n = 176 ) 
 
   
• Anteverted 
 
90 (51.1%) 70 (39.8%) 160 (90.9%) 
• Retroverted 
 
13 (7.4%) 3 (1.7%) 16 (9.1%) 
Uterine Mobility 
( n = 176 ) 
 
   
• Mobile 
 
40 (63.1%) 71 (40.3%) 111 (63.1%) 
• Restricted mobility 
 
52 (29.5%) 1 (0.6%) 53 (30.1%) 
• Fixed 
 
 
11 (6.2%) 1 (0.6%) 12 (6.8%) 
Uterosacral ligament 
( n = 176 ) 
 
   
• Normal 
 
77 (43.8%) 72 (40.9%) 149 (84.7%) 
• Thickened 
 
26 (14.8%) 1 (0.5%) 27 (15.3%) 
Uterosacral ligament 
Tenderness ( n = 176 ) 
 
   
• Tender 
 
8 (4.5%) 0 (0.0%) 8 (4.5%) 
• Non-tender 
 
95 (54.0%) 73 (41.5%) 168 (95.5%) 
Pouch of Douglas (POD) 
( n = 176 ) 
 
   
• Normal 
 
65 (36.9%) 63 (35.8) 128 (72.7%) 
• Obliterated 
 
38 (21.6%) 10 (5.7%) 48 (27.3%) 
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Upon comparing the physical examination findings with the presence of endometriosis, 
55 subjects (31.2%) who were found to have abdominal masses were confirmed to 
have endometriosis. Among these 55 subjects (n=55, 100%), most of the abdominal 
masses were found to have regular and well defined margins (n=50, 90.9%), smooth 
surface (n=55, 100%) and cystic in nature (n=53, 96.4%). However, there was no 
specific characteristic in the mobility of the masses which was associated with 
endometriosis (Table 4).  
The association of the physical examination findings and the diagnosis of 
endometriosis were looked into (Table 5). Despite more than 50% of the patients were 
found to have abdominal masses, its presence could not predict the diagnosis of 
endometriosis, with crude ratio of 0.81 (95% CI 0.45-1.49) and p value of 0.503. The 
rest of the characteristic of the abdominal mass could not specifically associated with 
the diagnosis of endometriosis (Table 5).  
The presence of endometriotic vaginal nodule made the diagnosis of endometriosis 
more likely (crude ratio 1.07, 95% CI 0.17-6.54). However, it was not statistically 
significant (p value 0.946). The presence of retroverted uterus, with restricted mobility 
and obliterated POD were found to be significantly associated with the diagnosis of 
endometriosis (crude ratio 3.37 (95% CI 0.92-12.29), p value 0.066; crude ratio 7.17 
(95% CI 2.07-24.86), p value 0.002; crude ratio 3.68 (95%CI 1.69-8.02), p value 0.001 
respectively) (Table 5). 
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Table 5: The correlation of physical examination findings with the diagnosis of 
endometriosis 
Variable b Crude OR (95% CI) Wald statistic (df) p value 
Abdominal mass 
   Absent 
   Present 
 
 
-0.21 
 
 
0.81 (0.45,1.49) 
 
1.00 
0.49 (1) 
 
 
0.503 
Margin of abdominal mass 
 No cyst 
 Regular 
 Irregular 
 
 
-0.24 
1.17 
 
1.00 
0.79 (0.43,1.45) 
3.23 (0.36,28.97) 
 
1.97 (2) 
0.58 (1) 
1.09 (1) 
 
0.373 
0.444 
0.295 
Surface of abdominal 
mass 
 No cyst 
 Smooth 
 Irregular 
 
 
 
-0.09 
-21.64 
 
 
1.00 
0.91(0.49,1.67) 
0.00 (0.00) 
 
 
0.09 (2) 
0.09 (2) 
0.00 (1) 
 
 
0.950 
0.760 
0.999 
Consistency of abdominal 
mass 
 No cyst 
 Cystic 
 Firm 
 Hard 
 
 
 
-0.31 
-0.05 
0.26 
 
 
1.00 
0.73 (0.35, 1.52) 
0.95 (0.45, 1.99) 
1.29 (0.11, 14.86) 
 
 
0.81 (3) 
0.69 (1) 
0.02 (1) 
0.04 (1) 
 
 
0.846 
0.406 
0.895 
0.837 
Mobility of abdominal 
mass 
 No cyst 
 Mobile 
 Restricted 
 Fixed 
 
 
 
-0.56 
0.25 
0.25 
 
 
1.00 
0.57 (0.28, 1.17) 
1.29 (0.60, 2.78) 
1.29 (0.11, 14.86) 
 
 
4.12 (3) 
2.32 (1) 
0.43 (1) 
0.04 (1) 
 
 
0.249‡ 
0.128‡ 
0.513 
0.837 
Tenderness of abdominal 
mass 
 No cyst 
 Tender 
 Non-tender 
 
 
 
  -0.84 
-0.13 
 
 
1.00 
0.43 (0.07, 2.73) 
0.88 (0.47, 1.62) 
 
 
0.87 (2) 
0.80 (1) 
0.17 (1) 
 
 
0.648 
0.371 
0.676 
Vaginal nodule 
 Absent 
 Present 
 
 
0.06 
 
 
1.07 (0.17, 6.54) 
           
          1.00 
0.01 (1) 
 
 
0.946 
Uterine position   
 Anteverted 
 Retroverted  
 
 
1.22 
 
 
3.37 (0.92, 12.29) 
 
1.00 
3.39 (1) 
 
 
0.066‡ 
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Uterus mobility 
 Mobile 
 Restricted 
 Fixed 
 
 
1.97 
0.58 
 
1.00 
7.17 (2.07,24.86) 
19.53 (2.43,156.83) 
 
9.77 (2) 
9.64 (1) 
0.22 (1) 
 
0.008† 
0.002† 
0.637 
Adnexae mass 
 Absent 
 Present 
 
 
0.59 
 
 
1.81 (0.80,4.08) 
 
1.00 
2.05 (1) 
 
 
0.152‡ 
Uterus Ligaments  
 Thickened 
 Not thickened 
 
 
-3.19 
 
 
0.04 (0.01,0.31) 
 
1.00 
9.56 (1) 
 
 
0.002† 
POD 
 Normal 
 Obliterate 
 
 
1.30 
 
 
3.68 (1.69,8.02) 
 
1.00 
10.78 (1) 
 
 
0.001† 
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5.2.3 Ultrasound findings 
Table 6 shows the ultrasound findings of the subjects in this study. Although from 
physical examination we found only 97 subjects with abdominal masses, a total of 158 
subjects (89.8%) were found to have pelvic masses detected from the ultrasound. 99 of 
them (n=99, 100%) are diagnosed to have endometriosis, in which 42 subjects (42.4%) 
had uniloculated mass and the rest were multiloculated (n=57, 57.6%). Majority of the 
multiloculated pelvic masses in patients with endometriosis were thin septum (n=54, 
94.7%). More than 95% of the pelvic masses found, did not have any papillary 
projection. In consistent with the examination finding, majority of the masses were 
cystic in nature (n=156, 98.7%). Majority of the subjects, who had endometriosis with 
presence of ovarian mass on ultrasound scan, noted to have thick sedimentation or 
ground glass appearance of the content of the mass (n=98, 98.9%) 
When correlating the ultrasound findings with the diagnosis of endometriosis, cystic 
pelvic masses with thin septae but without papillary projections and with thick 
sedimentation or ground glass appearance were more common to be diagnosed to 
have endometriosis (Table 6).  
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Table 6: Ultrasound findings in relation to the diagnosis of endometriosis  
Variables 
 
Endometriosis 
N (percentage) 
No Endometriosis 
N (percentage) 
Total 
N (percentage) 
Presence of ovarian mass 
 ( n = 176 ) 
   
• Present 99 (56.2%) 59 (33.5%) 158 (89.8%) 
• Absent 4 (2.3%) 14 (8.0%) 18 (10.2%) 
Locule of the mass 
( n = 158 ) 
   
• Uniloculated 42 (26.6%) 33 (20.9%) 75 (47.5%) 
• Multiloculated 57 (36.0%) 26 (16.5%) 83 (52.5%) 
Feature of the septum of 
the cysts ( n = 83 ) 
   
• Thin 54 (65.0%) 22 (26.6%) 76 (91.6%) 
• Thick 3 (3.6%) 4 (4.8%) 7 (8.4%) 
Papillary projection 
( n = 158 ) 
   
• Present 0 (0.0%) 2 (1.3%) 2 (1.3%) 
• Absent 99 (62.7%) 57 (36.0%) 156 (98.7%) 
Nature of the mass 
( n =158 ) 
   
• Cystic 99 (62.7%) 57 (36.0%) 156 (98.7%) 
• Solid 0 (0.0%) 2 (1.3%) 2 (1.3%) 
Content of the ovarian cyst  
( n = 158 ) 
   
• Clear 1 (0.6%) 50 (31.7%) 51 (32.3%) 
• Thick with 
sediments 
/Ground-glass 
appearance 
 
98 (62.0%) 9 (5.7%) 107 (67.7%) 
 
Subjects with ovarian mass found in ultrasonographic study had 5.87 risks of having 
endometriosis (Table 7). A multiloculated mass carried a higher risk as compared to 
uniloculated mass (crude ratio 7.67, 95% CI 2.30- 25.58, p value 0.001 and crude ratio 
4.46, 95% CI 1.34- 14.06, p value 0.015 respectively). Similarly, a cystic mass with 
thick sedimentation or ground glass appearance made the diagnosis of endometriosis 
stronger (Table 7). 
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Table 7: The correlation between the ultrasound findings and Ca125 with the diagnosis of 
endometriosis 
Variable b Crude OR (95% CI) Wald statistic (df) p value 
Scan Ovarian Mass 
 Absent 
 Present 
 
 
1.77 
 
 
5.87 (1.85,18.68) 
 
1.00 
8.99 (1) 
 
 
0.003† 
Locule of ovarian mass 
 No cyst 
 Uniloculated 
 Multiloculated 
 
 
1.49 
2.04 
 
1.00 
4.46 (1.34,14.06) 
7.67 (2.30,25.58) 
 
11.57 (2) 
5.94 (1) 
11.00 (1) 
 
0.003† 
0.015† 
0.001† 
Septum of ovarian mass 
 No cyst 
 Uniloculated 
 Multiloculated-thin 
 Multiloculated-
thick 
 
 
1.41 
2.13 
0.97 
 
1.00 
4.08 (1.22,13.64) 
8.45 (2.46,29.01) 
2.63 *0.41,16.94) 
 
13.59 (3) 
5.94 (1) 
12.00 (1) 
1.03 (1) 
 
0.004† 
0.015† 
0.001† 
0.310 
Papillary projection 
 No cyst 
 Absent 
 Present 
 
 
1.81 
-19.95 
 
1.00 
6.08 (1.91,19.35) 
0.00 (0.00) 
 
9.33 (2) 
9.33 (2) 
0.00 (1) 
 
0.009† 
0.002† 
0.999 
Nature of  mass by scan 
 No cyst 
 Cystic 
 Solid 
 
 
1.81 
-19.95 
 
1.00 
6.08 (1.91,19.35) 
0.00 (0.00) 
 
9.33 (2) 
9.33 (1) 
0.00 (1) 
 
0.009† 
0.002† 
0.999 
Content of ovarian mass 
 No cyst 
 Clear 
 Thick with 
sediments 
 
 
-2.65 
3.64 
 
1.00 
0.07 (0.01,0.68) 
38.11(10.34,140.42) 
 
55.31 (2) 
5.27 (1) 
29.93 (1) 
 
<0.001† 
0.022‡ 
<0.001† 
Ca125 0.04 1.04 (1.03, 1.05) 37.24 (1) <0.001† 
 
5.3 Serum Ca125 
The ROC (Receiver Operating Characteristic) curve was plotted to analyse the 
association in between the serum Ca 125 values with the diagnosis of endometriosis 
(Figure 4). The area under curve of the ROC curve was 0.8989 in correlation with the 
diagnosis of endometriosis, suggesting it as a good diagnostic tool for endometriosis. It 
was also noted that the value of serum Ca125 of ≥ 50u/ml had 80% sensitivity and 86% 
specificity to detect endometriosis. Further increment in the level was shown to be 
further increased the likelihood of endometriosis. However, levels of more than 200u/ml 
was shown to carry low sensitivity (7.7%) but high specificity (98.6%), which is not 
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suitable to be used for detection of endometriosis. Therefore, the cut off points of 
50u/ml and 200u/ml was used for further analysis of association.  
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Figure 4: The association between the levels of serum Ca125 and the diagnosis of 
endometriosis 
Using this cut off points, a correlation was made with the findings of endometriosis 
intraoperatively. As seen in Table 8, only 28 subjects (15.9%) were confirmed to have 
endometriosis with the serum level of <50u/ml or >200u/ml. In contrast, 75 subjects 
(42.6%) had endometriosis with the serum Ca125 levels was between 50 to 200u/ml. 
When a simple logistic regression test was performed, this level (50-200u/ml) was 
strongly associated with the presence of endometriosis (crude OR 19.05; 95% CI 8.38-
43.32; p value <0.001) (Table 9).  
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Table 8: Serum Ca125 levels in relation with endometriosis 
Serum Ca125  
(u/ml) 
Endometriosis  
N (%) 
No Endometriosis 
N (%) 
Total 
< 50  12 (6.8 %) 53 (30.1%) 65 (36.9%) 
50 - 200 75 (42.6%) 9 (5.1%) 84 (47.7%) 
>200 16 (9.1%) 11 (6.3%) 27 (15.3%) 
Total 103 (58.5%) 73 (41.5%) 176 (100%) 
 
Table 9: Simple logistic regression test to associate the levels of serum Ca125 with 
endometriosis 
Serum Ca 125 
(u/ml) 
b Crude OR 
(95% CI) 
Wald p Value 
< 50 or > 200   1.00  
50 - 200 2.95 19.05 
(8.38, 43.32) 
49.40 < 0.001 
 
5.4 Correlation of clinical features, ultrasound findings and 
serum Ca125 with the diagnosis of endometriosis 
From the previous simple logistic regression test performed on various clinical features 
and ultrasound findings, it was noted that the below features were found to be 
significantly associated with the presence of endometriosis: 
1. Presence of subfertility 
2. Dysmenorrhoea according to its severity 
3. Dyspareunia according to its severity 
4. Restricted mobility of the uterus 
5. Obliterated POD 
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6. The presence of multiloculated, cystic ovarian mass with thick sedimentation in 
ultrasonographic study 
7. Serum Ca125 
To evaluate the combination of these features with the diagnosis of endometriosis, a 
multiple logistic regression test was performed (Table 10). It was noted that the 
presence of dysmenorrhoea, regardless of it severity, the presence of ovarian mass 
with thick sedimentation and the level of serum Ca125 between 50 to 200u/ml were 
significantly correlate with the diagnosis of endometriosis. 
5.5 Staging of endometriosis 
The staging of endometriosis was performed during the operation, based on the 
revised ASRM classification. It was found that out of the 103 subjects who were 
diagnosed to have endometriosis, 4 subjects (3.9%) had stage I endometriosis, 12 
subjects (11.7%) were in stage II, 43 subjects (41.7%) and 44 subjects (42.7%) were in 
stage III and stage IV respectively (Table 11).  
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Table 10: The association between the significant variables with endometriosis 
 
 
Variable b Adjusted OR (95% CI) LR statistic (df) p value 
Ca125 0.03 1.03 (1.02, 1.05) 22.44 (1) <0.001 
Dysmenorrhoea Severity     
   No pain  1.00 14.27 (3) 0.003 
   Mild 0.30 1.35 (0.13, 13.64) 0.06 (1) 0.800 
   Moderate 2.78 16.04 (4.41, 58.34) 1.34 (1) 0.248 
   Severe 3.33 27.89 (1.89, 411.95) 5.87 (1) 0.015 
Content of ovarian mass     
   No cyst   55.31 (2) <0.001 
   Clear -2.66 0.07 (0.007,0.678) 5.27 (1) 0.022 
   Thick with sediments 3.64 38.11 (10.34,140.42) 29.93 (1) <0.001 
     
Uterus Position     
   Anteverted   1.00  
   Retroverted 18.53 111693393 (0.00) 3688.70 (1) 0.996 
     
Uterine Mobility     
   Mobile   1.00  
   Restricted mobility 19.15 20668373.30 (0.00) 0.00 (1) 0.996 
   Fixed 35.84 3.66 (0.00) 0.00 (1) 0.995 
     
Pouch of Douglas     
   Normal   1.00  
   Obliterated 0.463  1.59 (0.25,10.07) 0.242 (1) 0.623 
     
     
Locule of ovarian mass     
   No cyst   0.65 (2) 0.722 
   Uniloculated -1.83 0.16 (0.00,30.00) 0.47 (1) 0.493 
   Multiloculated -0.38 0.68 (0.00,132.70) 0.02 (1) 0.888 
     
Septum of ovarian mass     
   No cyst   12.84 (3) 0.005 
   Uniloculated (no septum) 1.89 6.64 (1.59,27.65) 6.77 (1) 0.009 
   Multiloculated-thin septum 2.39 10.91 (2.58,46.05) 10.58 (1) 0.001 
   Multiloculated-thick septum 0.336 1.40 (0.14,13.69) 0.08 (1) 0.773 
     
46 
 
  
Table 11: Stages of endometriosis diagnosed intraoperatively 
Stages of  Endometriosis  
 
Frequency (N) Percentage (%) 
Stage I  
(Minimal; score 1-5) 
 
4 3.9 
Stage II 
(Mild; score 6-15) 
 
12 11.7 
Stage III 
(Moderate; score 16-40) 
 
43 41.7 
Stage IV  
(Severe; score> 40 ) 
 
44 42.7 
Table 12 shows the distribution of the features strongly correlate with endometriosis 
according to the stages of disease found. The significant features were then tested to 
see their correlation with the stage of the disease, as shown in Table 13. Symptoms of 
severe dysmenorrhea were statistically significant in correlation with all the stages of 
endometriosis. It was found that the presence of serum Ca125 between 50 to 200u/ml 
has three times risk for stage III to IV endometriosis. The rest of the clinical 
manifestations did not correlate well with the stages of endometriosis. 
Table 12: Distribution of various clinical features in relation to the stages of 
endometriosis 
Variables Stage of endometriosis 
Stage I 
(N) 
Stage II 
(N) 
Stage III 
(N) 
Stage IV 
 (N) 
Dysmenorrhoea 
(n=100) 
• Mild  
• Moderate 
• Severe 
 
 
0 
2 
2 
 
 
1 
8 
3 
 
 
14 
16 
11 
 
 
9 
17 
17 
Ovarian cyst with 
thick sedimentation 
1 12 43 44 
47 
 
Table 13: The correlation between dysmenorrhoea, cystic with thick sedimentation 
ovarian mass and serum Ca125 with stages of endometriosis 
Variable 
Stage of 
endometrio
sis 
b Crude OR 
(95% CI) 
Wald 
statistic (df) 
p value 
Mild 
Dysmenorr
hoea 
Stage I  -21.12 0.00 0.00 (1) 0.999 
Stage II -2.32 0.09 
(0.01,0.80) 
4.08 (1) 0.031† 
Stage III -0.65 0.52 
(0.24,1.15) 
2.59 (1) 0.107‡ 
Stage IV -1.28 0.28 
(0.12,0.66) 
8.37 (1) 0.004† 
      
Moderate 
dysmenorr
hoea 
Stage I  0.30 1.35 
(0.18,10.15) 
0.09 (1) 0.768 
Stage II 0.99 2.71 
(0.75,9.81) 
2.31 (1) 0.129‡ 
Stage III -0.22 0.80 
(0.37,1.74) 
0.31 (1) 0.578 
Stage IV -0.16 0.85 
(0.39,1.83) 
0.17 (1) 0.683 
      
Severe 
dysmenorr
hoea 
Stage I  3.65 23.33 
(2.39,227.05) 
7.36 (1) 0.007† 
Stage II 2.05 7.78 
(1.36,44.51) 
5.31 (1) 0.021† 
Stage III 2.08 8.02 
(2.09,30.74) 
9.23 (1) 0.002† 
Stage IV 2.69 14.69 
(3.98,54.19) 
16.28 (1) <0.001† 
      
Ovarian 
cyst with 
thick 
sedimentati
on 
Stage I  0.86 2.37 
(0.22,25.31) 
0.51 (1) 0.475 
Stage II 23.17 >100 (0.00,) 0.00 (1) 0.998 
Stage III 23.17 >100 (0.00,) 0.00 (1) 0.997 
Stage IV 5.01 >100 
(30.73,725.6) 
38.52 (1) <0.001† 
      
Serum 
Ca125 50-
200u/ml 
Stage I  0.86 2.37 
(0.22,25.31) 
0.51 (1) 0.475 
Stage II 0.35 1.42 (0.87, 
7.56) 
0.17 (1) 0.679 
Stage III 3.44 31.11 
(11.02,87.82) 
42.16 (1) <0.001↑ 
Stage IV 3.63 37.59 
(12.93,109.3) 
44.34 (1) <0.001↑ 
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5.6 Histopathology examination 
Whenever possible, tissue specimen from the subjects noted to have endometriosis, 
was taken from the subjects during the operation. Out of 103 patients who were 
diagnosed to have endometriosis, 92 patients were confirmed to have endometriosis 
histopathologically (Table 14).  
Table 14: Histopathology diagnosis of endometriosis 
Histopathology diagnosis of  
Endometriosis 
 
Endometriosis 
(N, percentage ) 
No Endometriosis 
(N, percentage) 
Positive 
Negative  
92 (52.3%) 
          11 (6.2%) 
0 (0.0%) 
73 (41.5%) 
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6.0  DISCUSSION 
6.1 GENERAL 
This cross sectional study evaluated the accuracy of  clinical manifestation (including 
symptoms, physical examination, ultrasonography features) and serum Ca 125 levels 
to diagnose endometriosis, in comparison with laparoscopic or laparotomy findings with 
or without histopathological examination. This study aimed to create a scoring system 
named CliEndomet, which consists of various clinical manifestations and Ca 125 level 
which suggestive of  endometriosis. 
The gold standard for detecting endometriosis disease is direct visualization via 
laparoscopy or laparotomy with or without histopathology confirmation (Gerard A. et. al, 
2012 ). Latest guideline by ESHRE on endometriosis (ESHRE, 2013) stated that the 
combination of laparoscopy and the histological verification of endometrial glands 
and/or stroma is considered for the diagnosis of endometriosis. The GDG (Guideline 
Development Group) recommends that endometriosis diagnosed by a positive 
laparoscopy with histology, even though negative histology does not exclude it. Thus, 
in this study, the clinical diagnosis of endometriosis was done according to positive 
laparoscopy (direct visualization) with or without histopathology confirmation. Ultimately, 
diagnosis of endometriosis requires a careful clinical evaluation in combination with 
judicious use and critical interpretation of laboratory tests, imaging techniques and, in 
most instances, surgical staging combined with histological examination of excised 
lesions (Robert Z. et.at, 2003).  Many international studies had been done and 
published in effort to diagnose endometriosis without surgical intervention.  However, 
none of the presenting symptoms or signs was pathognomonic towards endometriosis. 
The predictive value of any one symptom or set of symptoms remains uncertain, and 
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establishing the diagnosis of endometriosis on the basis of symptoms alone can be 
difficult (RCOG, 2006). 
Serum Ca 125 level has been evaluated in many previous studies in order to diagnose 
endometriosis. Moderate elevations of serum Ca 125 has been observed in patients 
with moderate to severe disease, but the specificity and sensitivity of this biomarker 
alone have not been proven adequate for clinical diagnosis (Pratibha A. et.al, 2006). 
The sensitivity of serum Ca 125 is too low for it to be used alone as a screening or 
diagnostic test for endometriosis. 
This study aimed to investigate whether the diagnosis of endometriosis might be 
improved by compilation of symptoms, physical examinations, ultrasound features and 
serum CA 125 level, comparing with surgical staging and/or histopathology 
examination. Few and limited studies had been done internationally for the same 
objective, suggested combination use of clinical indexes may be a reliable non-surgical 
diagnostic method for endometriosis, but none of those studies has come out with a 
scoring system, which correlate the history, clinical examination, ultrasound findings 
and serum CA 125 level. 
6.2 DEMOGRAPHIC DATA 
There were 176 patients involved in this study, out of which 103 of them were 
diagnosed to have endometriosis and 73 patients with no surgical evidence of the 
disease. Endometriosis is almost always detected in women of reproductive age 
(Robert Z.et.al 2003). The mean age of the women in this study was 35.41 ± 6.90 
years. The majority being between 30 and 40 years of age for both cases and control. 
This is nearly the same as previous study by Daniele G.et.al., published by ASRM 
Elsevier in 2003, with mean age 37.30 ± 6.40 years.  Possible reason for these women 
seek treatment late at their 30’s could be due to reduce in ability to cope with the 
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symptoms related to endometriosis when the disease progress (Houston, 1984; 
Hadfield et.al., 1996).  
According to study done by Robert Z.et.al, 2003, the protective effect of pregnancy 
appears to wane gradually and an increased risk of endometriosis has been observed 
with an increase in the number of years since the last child birth. However, there was 
not much difference in the mean duration of last child birth among patients with 
endometriosis compared with those without endometriosis (4.42 ± 5.53 years versus 
4.81 ± 4.39 years respectively) noted in this study. 
The present study found that majority of the subjects with endometriosis were 
nulliparous or low parity (para 1 or 2), comprised of 68.0%, and most of them have 
history of sub-fertility (61.2%).  
The mean duration of subfertility for patients with endometriosis was 4.69 ± 5.62 years, 
which was longer than mean duration of subfertility for patients without endometriosis, 
i.e. 3.38 ± 5.05 years. This finding is in tandem with the fact that endometriosis is 
associated with reduced fertility. Robert Z et. al and Sangi H. P. et. al. also found 
similar findings in their studies (Robert Z et. al, 2003; Sangi H.P. et. al., 1995).   
6.3  CLINICAL ASSESSMENT 
6.3.1 Clinical presentation 
Although women with endometriosis may be asymptomatic, symptoms are common 
and typically include pelvic pain. In this study, the clinical symptoms of dysmenorrhea, 
dyspareunia, ovulation pain, dyschezia and non-specific pelvic pain were evaluated.  
Among the 176 subjects, 169 subjects (96.0%) presented with dysmenorrhea in this 
study. 56.8% out of patients with dysmenorrhea were diagnosed to have endometriosis, 
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whereas only 3 patients (1.7%) with endometriosis did not presented with 
dysmenorrhea. Most of the patients with endometriosis were categorized in moderate 
(43.0%) and severe (33.0%) group of severity of dysmenorrhea. This finding was 
similar with the study by Eskenazi et al in 2001, where there were higher prevalence of 
endometriosis among patients with moderate to severe degree of dysmenorrhea 
(Eskenazi et al, 2001). Cramer and his associates (1986) demonstrated a positive 
correlation between the severity of dysmenorrhea and the risk of endometriosis. 
However, the current revised American Society for Reproductive Medicine (rASRM) 
classification of endometriosis poorly predicts symptoms (Dietmar H.et.al, 2012). 
Women with extensive disease (stage IV) may have mild symptoms, whereas those 
with minimal disease (stage I) may presented with significant pain. This trend was seen 
in my study, which 9 patients who presented with mild dysmenorrhea were diagnosed 
to have stage IV endometriosis, whereas 5 patients who presented with severe 
dysmenorrhea had stage I and II endometriosis. Many researches have been published, 
revealing no association between the stage of endometriosis and the severity of 
dysmenorrhea as well as non-menstrual pelvic pain (Robert Z.et.al, 2003).  Evidence 
regarding the association between the intensity of pain and morphologic features of the 
endometriotic implant was inconclusive and contradictory (Robert Z et. al, 2003). In a 
multicentre cross-sectional observational study, found no significant correlation 
between stage and site of endometriosis and severity of dysmenorrhea, non-menstrual 
pain and dyspareunia. 
Endometriosis-related dyspareunia is usually positional and most intense upon deep 
penetration, it is usually associated with endometriosis of cul-de-sac and rectovaginal 
septum (Robert Z.et.al, 2003). Endometriosis-related dyspareunia is suspected if pain 
developed after years of pain-free intercourse (Ferrero, 2005). This study had 
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demonstrated only 19 out of 26 subjects (18.4%) who presented with dyspareunia were 
confirmed to have endometriosis. Though the simple logistic regression test had shown 
that dyspareunia was associated with high prevalence of endometriosis, this finding 
was found not to be statistically significant, perhaps due to the small number of 
subjects. Because of this, its association with the stage of disease was not analysed. In 
contrast to this finding, Prathiba et. al. in 2006 had found a higher prevalence of 
dyspareunia in endometriotic patients (25-40%), which could be caused by a higher 
number of studied subjects.  
Ovulation pain may represent an extension of dysmenorrhea, in severe cases, patients 
may suffer from pain throughout the menstrual cycle. The ovulation pain has been 
reported in 57-68% of women with endometriosis and pain (Gruppo et.al, 2001). The 
number of subjects with ovulation pain in this study was too small (N=2) to be 
commented or concluded.  
Dyschezia, or painful defecation, is less common to occur than other clinical 
manifestation in endometriosis. This was evidenced by only 2 patients with 
endometriosis in my study complaint of dyschezia, with pain score 2/10 and 4/10 
respectively. This symptom typically reflects rectosigmoid involvement with 
endometriotic implants (Azzena, 1998). 
6.3.2 Physical Examination 
Physical examination may provide a broad range of findings. In mild endometriosis, the 
gynaecologic examination may be unremarkable. Abdominal examination is usually not 
significant unless patient presented with abdominal mass or in rare instances of scar 
endometriomas, painful swelling or focal tenderness (Robert Z et al, 2003). In this 
study, 97 subjects were noted to have abdominal mass and out of this number, 55 of 
them (31.2%) were confirmed to have endometriosis. This finding was consistent with 
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the prevalence of endometrioma, which was reported to be between 17 to 44% of all 
women with endometriosis (Patreli et.al, 2011). Endometrioma will typically cystic in 
nature, with uni or multiloculated surface, regular margin and can be tender if palpated 
during menses. The finding of the endometrioma in this study was consistent with 
those features, in which more than 90% of the masses were found to have regular 
margin, smooth surface and cystic in consistency. Usually endometrioma was tender 
on palpation but in this study, 96.4% of the masses were non- tender. Although 
endometrioma typically associated with restricted mobility due to the presence of 
adhesion, only 32 out of 55 patients with endometrioma were found to be restricted 
mobility. 
Ideally the gynaecologic examination should be performed while the patient 
experiences at least some symptoms, preferable during menstruation, when it may be 
easiest to detect and localize areas suspected of harbouring endometriosis (Robert Z 
et.al, 2003). However, almost all the vaginal examinations were done when the 
subjects were not menstruating, as the cultural practised by the patients here refused 
for vaginal examination during having menses. According to Chapron et al in 2002, 
lesions were visible during speculum examination in only 14.4% and a classic, painful, 
spheric nodule was palpable during manual examination in 43.1% of patients. 
Speculum inspection may reveal bluish implants typical of endometriosis or red, 
hypertrophic lesions bleeding on contact, usually in the posterior fornix. Only 5 subjects 
were noted to have vaginal nodule in this study, and only 3 of them were confirmed to 
have endometriosis, although this showed high sensitivity (60%) with low specificity in 
detecting endometriosis, but was not statistically significant in view of small number of 
subjects. 
55 
 
Positive physical signs are found on bimanual and rectovaginal examination of pelvic 
structures. Palpation of the uterus in patient with endometriosis may reveal retroversion, 
decreased or absent mobility, and tenderness (Robert Z.et.al, 2003). This study 
however demonstrated majority of the subjects with endometriosis (n=90, 87.3%) have 
anteverted uterus. 63 subjects (61.2%) had restricted mobility. The position of the 
uterus was not found to correlate well with the presence of endometriosis (p value 
0.066). On the other hand, a restricted mobility uterus was highly and significantly 
correlate with endometriosis (crude OR 7.17; 95% CI 2.07- 24.86; p value 0.002). But 
when this feature was tested using the multiple logistic regression test, the correlation 
was cancelled and found not to be significant. Retroverted with restricted mobility of 
uterus are more common in severe endometriosis (Chapron et.al, 2002). This trend 
was seen in my study. There were 26 subjects (25.2%) out of 103 patients with 
endometriosis, had thickened uterosacral ligament, 2 of them (7.69%) were classified 
as stage 2 endometriosis, 10 subjects (38.5%) in stage III and 14 subjects  (53.8%) in 
stage IV. Only 8 patients (7.8%) had tenderness over the uterosacral ligament, which 
were not sensitive nor specific findings in diagnosing endometriosis. Uterosacral 
ligament nodularity or thickening and tenderness may reflect active disease or scarring 
along the ligament (Chapron et.al, 2002). 38 patients with endometriosis (36.9%) had 
obliterated Pouch of Douglas (POD). This figure was similar to the percentage reported 
by Reid S. et.al in 2013, which there was nearly 30% of  endometriosis patients had 
obliterated POD.  Majority of them had more severe stage of endometriosis (stage III 
and stage IV).  
Although pelvic organ palpation may assist in diagnosis, the sensitivity and specificity 
of focal pelvic tenderness in detecting endometriosis displays wide variation and 
ranges from 36 to 90 per cent and 32 to 92 per cent, respectively (Chapron, 2002; 
Eskenazi, 2001; Koninckx, 1996). According to Robert Z.et.al in 2003, a normal clinical 
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examination does not rule out the diagnosis of endometriosis, and pelvic examination 
showed poor sensitivity, specificity and predictive values. A prospective study 
validating non-surgical approaches to diagnosis of endometriosis found that pelvic 
examination was a reliable predictor of ovarian endometriomas but was not helpful in 
prediction of non-ovarian lesions (Robert Z. et.al, 2003). 
6.4 Ultrasonographic findings 
Ultrasonographic examination is particularly helpful in the evaluation of endometriotic 
cysts but has a limited role in the diagnosis of adhesions or superficial peritoneal 
implants (Friedman H.et.al, 1985). Small endometriotic plaques or nodules may 
occasionally be seen, but these findings are inconsistent (Carbognin, 2007). 
Transvaginal sonographic (TVS) approach was done in most of the patients in this 
study as it is more sensitive to detect small pelvic masses than transabdominal 
ultrasound. Endometriomas can be diagnosed by TVS with adequate sensitivity if they 
are 20mm or greater in diameter (Chapron et.al, 2002). According to Moore.et.al in 
2002, the sensitivity and specificity of TVS to diagnose endometriomas range from 64 -
90% and from 22-100%, respectively. This study had demonstrated that 
ultrasonographic examination carried a high sensitivity (96.1%) but low specificity 
(19.2%) in diagnosing endometriomas. 99 out of 103 subjects with endometriosis were 
noted to have ovarian mass during ultrasound scan. Their presence was found to 
correlate well with endometriosis (crude OR 5.87, 95% CI 1.85-18.68; p value 0.003). 
Majority of the cases that were confirmed to have endometriomas, when ovarian mass 
were detected during ultrasound, had features of multiloculated mass (55.3%), with thin 
septation (94.7%), cystic in nature (100%), and ground-glass appearance or thick with 
sediments (98.9%), without papillary projection.  
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Among the features of ovarian mass, the presence of cystic mass with thick 
sedimentation was found to be more than 38 times associated with endometriosis 
(crude OR 38.11; 95% CI 10.34- 140.42; p value < 0.001). These finding, were 
consistent with the statement by Athey et.al in 1989 that endometriomas often present 
as cystic structures, with low-level internal echoes (95%). Patel M.et.al in 1999 also 
found that an adnexal mass with diffuse low-level internal echoes and absence of 
particular neoplastic features is very likely to be an endometrioma if multilocularity or 
hyperechoic wall foci are present. According to Nezhat et.al in 1992, the 
endometriomas may be unilocular, but are often multilocular when more than 3cm in 
diameter. Occasionally endometriomas may have thick septation and thickened walls. 
Diagnostic accuracy of ultrasound may be enhanced by colour Doppler flow studies 
which demonstrate pericystic flow (Kurjak, 1994).  
6.5  BIOCHEMICAL MARKER  Ca 125 
Elevated Ca 125 levels has been shown to positively correlate with the severity of 
endometriosis (Hornstein, 1995). This study analysed the performance of serum Ca 
125 measurement in women with endometriosis. Timing of blood collection for Ca 125 
in relation to the menstrual cycle significantly affects this test. As suggested by 
Koninckx et.al, 1996, almost all the blood samples in this study were taken during 
menstruation, as this test would be more reliable and clearly elevated than testing in 
follicular phase.  
23 studies have investigated serum Ca 125 in women with surgically confirmed 
endometriosis. Those studies have shown only 28% sensitivity and 98% specificity to 
detect endometriosis. Similarly, this study had also shown a low sensitivity (30%) but 
high specificity (98%). Could the low sensitivity alter the different level of serum Ca125. 
Therefore, a ROC analysis was performed for the subjects. The ROC analysis had 
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shown that the AUC for serum Ca125 was 90%, indicating 90% accuracy in predicting 
the presence of endometriosis. From the curve, it was noted the levels between 50 to 
200u/ml carried 80% sensitivity and 86% specificity, with a corresponding likelihood 
ratio of 5.8. It was found that the sensitivity of the serum Ca125 reduces for the levels 
above 200u/ml, even though the specificity increases. Therefore, the levels between 50 
to 200u/ml were taken as the reference values for the correlation. Using this reference 
value, it was found that 75 out of 103 subjects with endometriosis has serum Ca125 
levels at this levels (50 to 200u/ml), with crude OR of 19.05 (95% CI 8.38 – 43.32; p 
value < 0.001).  
6.6 Formation of the CliEndomet 
The most important aim of this study is to find a non-surgical way that is highly 
suggestive of endometriosis. Any single use of clinical indexes achieved poor 
sensitivity in diagnosing endometriosis (J.Leng et.al, 2006). In women with 
endometriosis, a normal CA 125 neither confirms the absence of endometriosis nor 
predicts recurrence (Ozaksit et.al, 1995). Therefore, the use of CA 125 levels alone to 
diagnose endometriosis is not warranted. There are few studies have been done to 
evaluate mutual dependency between a medical history, physical examination, imaging 
and serum CA 125 measurement, to arrive at a diagnosis without surgery,  but none 
come out with a proper conclusion yet nor proven clinically useful on their own. 
Therefore, a multiple logistic regression test to evaluate the significant features to 
diagnose endometriosis was performed. It was found that dysmenorrhoea, 
ultrasonographic findings of cystic ovarian mass with thick sedimentation and serum 
Ca125 between 50 to 200u/ml significantly associated with endometriosis. A 
combination of these features may be able to help in diagnosing endometriosis. 
Therefore, a scoring system that is highly suggestive of endometriosis using these 
features, named CliEndomet, was formed (Figure 5). From the total score which was 
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obtained using the CliEndomet scoring system, the risk of a patient to have 
endometriosis could be assessed.  
6.7  Surgical findings versus histopathological results 
Laparoscopy with or without histopathology confirmation is considered to be the ‘gold 
standard’ for the diagnosis of endometriosis (Gerard A.et.al, 2012). Several articles, 
however, reported that laparoscopy diagnosis is often an inaccurate determination. 
This is mainly due to variable appearance of the endometriotic lesions with different 
colours and morphology visualized during laparoscopic examinations. American 
Society for Reproductive Medicine (ASRM, 1997) suggested that relying solely on 
laparoscopic findings without histologic confirmation often results in overdiagnosis. 
Therefore, Tommaso et.al in 2003 concluded that a diagnostic laparoscopy without 
histologic confirmation of the disease may lead to incorrect assignment of the diagnosis, 
and very subtle or minimal lesions may be more difficult to diagnose during operation 
and this may lead to an underestimate of the prevalence of disease. 
Laparoscopic visualization of ovarian endometriomas has a sensitivity and specificity of 
97% and 95%, respectively (Vercellini, 1991). Due to this, ovarian biopsy is rarely 
required for diagnosis. 
The current guideline on endometriosis by ESHRE, 2013 recommends that positive 
laparoscopy with histology is used for diagnosis of endometriosis. However, this 
guideline also stated that negative histology does not exclude the diagnosis. Thus, in 
this study, the clinical diagnosis of endometriosis were based on positive laparoscopy 
with direct visualization with or without histopathological confirmation. 
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Figure 5: CliEndomet; The Clinical Scoring System that help in diagnosis of 
Endometriosis 
 
 
 
 
fl ~~ CliEndomet mu~~ ~_ Mu.'ll 
-_, ... -.. .... , ........... The Diagnostic Clinical Scoring System For 
Endometriosis 
Name: 
· ·· ·· ·· -
. . .. . . .. . . . . . .. .. .. .... ..... ... Registration no: ... ... . .... ... ...... .. 
Endometriosis: Yes No Date: 
----- -- -- -------- - ---- ------- -· -- · -· --
Recommended treatment: 
Total score: ................................... . ............................ ....... ............... 
........ ......... ............ ...................... 
............................. .. .................... 
Criteria Score 
Dysmenorrhea : 
. No dysmenorrhea 0 
. Mild dysmenorrhea 1 
• Moderate dysmenorrhea 2 
. Severe dysmenorrhea 3 
Ultrasonographic findings : 
• Solid ovarian mass or cystic with papillary projections 0 
. Uniloculated, serous ovarian cyst 1 
. Multiloculated cyst with thick sedimentations (ground-glass 2 
appearance ) 
Level of serum CA 125 : 
. < 50 U/ml or > 200 U/ml 0 
. 50 - 200 U/ml 2 
The CliEndomet formula: 
Total score= (Dysmenorrhoea+ Ultrasonographic findings + Ca125) x 2 
Risk of having endometriosis: 
Total score Possibility of endometriosis 
Score 0 - 2 Unlikely 
Score 4-6 Low possibility 
Score 8 -10 Moderate possibility 
Score 12- 14 High possibility 
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In a prospective study by Walter et.al in 2001, correlated visual diagnosis of 
endometriosis at laparoscopy with final histological confirmation in 44 patients. Walter 
et.al concluded that, with the use of strict histological criteria resulted in lower rates of 
confirmed endometriosis as visually detected endometriosis was observed in 36% of 
cases but confirmed histologically in only 18% of cases.  The finding was different in 
our study, where 103 patients (58.5%) were diagnosed to have endometriosis either via 
direct visualization during laparoscopic examination with or without histopathological 
confirmation. 92 patients in this study (52.3%) were confirmed histopathologically. The 
residual 11 patients (6.3%) either no specimen taken (eg. ablative method used 
intraoperatively and no specimen taken for HPE) or inadequate samples for 
histopathological examination, but diagnosis via direct visualization without biopsy still 
considered as a reliable method to diagnose endometriosis, regardless of the stages of 
disease.  
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7.0 VALIDATION  OF  CLIENDOMET 
7.1  VALIDATION OF  CLIENDOMET SCORING SYSTEM 
 
Table 15: The frequency and distribution of total score by CliEndomet  
Total Score 
 
Frequency (N) Percentage (%) 
0 
 
0 0 
2 
 
14 8.0 
4 
 
25 14.2 
6 
 
40 22.7 
8 
 
28 15.9 
10 
 
29 16.5 
12 
 
26 14.7 
14 
 
14 8.0 
 
 
 
 
Table 16: The correlation between the possibility of endometriosis (from CliEndomet) 
with diagnosis of endometriosis  
Possibility of endometriosis Endometriosis 
(N, percentage ) 
No Endometriosis 
(N, percentage) 
Unlikely (score 0-2) 
Low possibility (score 4-6) 
Moderate possibility (score 8-10) 
High possibility (score 12-14) 
1 (0.5%) 
12 (6.8%) 
51 (29.0%) 
39 (22.2%) 
13 (7.4%) 
53 (30.1%) 
6 (3.5%) 
1 (0.5%) 
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Table 17: Distribution of possibility of endometriosis (from CliEndomet) in relation to the 
stages of endometriosis 
Possibility of 
endometriosis 
Stage of endometriosis 
Stage I 
(N,%) 
Stage II 
(N,%) 
Stage III 
(N,%) 
Stage IV 
 (N,%) 
Unlikely  
 
Low possibility 
 
Moderate possibility 
 
High possibility 
 
0 (0%) 
 
3 (2.9%) 
 
1 (0.9%) 
 
0 (0%) 
1 (0.9%) 
 
3 (2.9%) 
 
6 (5.9%) 
 
2 (1.9%) 
0 (0%) 
 
4 (3.9%) 
 
26 (25.3%) 
 
13 (12.6%) 
0 (0%) 
 
2 (1.9%) 
 
18 (17.5%) 
 
24 (23.4%) 
 
Table 18: Categories of possibility of endometriosis (from CliEndomet) in relation with 
diagnosis of endometriosis 
Category of 
possibility of 
endometriosis 
Endometriosis 
(N, %) 
No Endometriosis 
(N, %) 
Total 
(N, %) 
Unlikely and low 
possibility 
13 (7.4%) 66 (37.5%) 79 (44.9%) 
Moderate and high 
possibility 
90 (51.1%) 7 (4.0%) 97 (55.1%) 
Total (N, %) 103 (58.5%) 73 (41.5%) 176 (100%) 
 
7.2  SENSITIVITY, SPECIFICITY, POSITIVE PREDICTIVE VALUE 
AND NEGATIVE PREDICTIVE VALUE OF CLIENDOMET 
Sensitivity of  CliEndomet :                         
 
Specificity of  CliEndomet :  
 
 
 
    90 
______   x 100% = 87.4% 
   103 
      66 
______   x 100% = 90.4% 
      73 
64 
 
 
 
Positive Predictive Value :  
 
 
 
 
Negative Predictive Value :  
 
 
 
 
 
 
 
From the scoring system CliEndomet, we have calculated retrospectively the score of 
possibility of endometriosis on the same sample of patients ( N = 176), noted there was 
high sensitivity 87.4%, high specificity 90.4% with positive predictive values 92.8% and 
negative predictive value 83.5%. 
Subjects who fall into moderate or high possibility of endometriosis ( N = 97 ), 90 of 
them (92.8%) had been diagnosed endometriosis (either via direct visualization from 
laparoscopy or laparotomy, with or without histopathology confirmation). Another 79 
subjects fall into unlikely or low possibility category, 66 of them (83.5%) did not have 
endometriosis. 
However, the accuracy of this CliEndomet scoring system is better to be validated in 
another samples of patients, to test the sensitivity and specificity of this scoring system. 
 
 
 
90 
___  x 100% = 92.8% 
97 
66 
___  x 100% = 83.5% 
79 
65 
 
8.0  CONCLUSION  AND  SUGGESTIONS 
The clinical presentation of endometriosis varies in terms of clinical symptoms, signs 
found during physical examination, ultrasonographic findings of ovarian mass and 
elevation of serum Ca125. Standing alone, each of these features fails to detect 
endometriosis accurately.   
This study has demonstrated a few significant clinical menifestations of endometriosis, 
i.e. the presence of dysmenorrhoea, an ultrasonographic finding of a cystic ovarian 
mass, which contains thick sedimentation and an elevated serum Ca125 in the range 
between 50 to 200u/ml. Using the combination of these features, a clinical suggestive 
scoring system, named as CliEndomet, was formulated. 
Endometriosis is highly suggestive by using the CliEndomet scoring system, which 
takes into consideration of several significant clinical parameters. This scoring system 
was designed to detect all stages of the disease and thus could be used to all patients 
suspected of having endometriosis.  However, the accuracy of the CliEndomet is better 
to be validated in another sample of patients. 
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9.0 LIMITATION  AND  RECOMMENDATION 
The findings in the present study may be limited by a few factors, and recommendation 
for the betterment of the study was made as below:  
• This study was done in 2 hospitals in Kelantan, the presentation and outcomes 
might differ in other places. Ideally multi-centered study with collaboration with 
other centre, will give more variations in the results. Although the CliEndomet 
scoring system is formed based on data obtained from a carefully characterized 
study population, it remains necessary to validate these results on a different 
study population. 
• There was difference in the numbers of patients in different stages of 
endometriosis, which was not equally distributed. Therefore we would suggest 
for balancing the numbers of cases for each stages of endometriosis in future 
research and to minimize bias on the results. 
• The usage of CliEndomet scoring system could be used and extended to non-
sexually active patients with pelvic pain. 
• The accuracy of Cli-Endomet scoring system is not yet validated. Thus, a 
further validation study (on different sample of patients) is required to test the 
sensitivity and specificity of this scoring system in helping the diagnosis of 
endometriosis. We recommend another study with this objective to be done on 
a new group of patients in near future. 
• This scoring system is helpful in diagnosis of endometriosis but have limitation 
in further division into the stages of the disease. Should it proven to be accurate, 
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its usage could also be extended to determine the severity of the disease in 
order to predict its prognosis. 
• This scoring system aimed in selecting patient who is moderately or highly 
suggestive to have endometriosis, however, if this test has been validated in 
future study, the further treatment of patient will be individualized, either medical 
or surgical treatment. However, if associated with huge pelvic mass 
(endometrioma), surgery may be needed, which is beyond the scope of this 
study. 
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APPENDIX 2 : CLINICAL RESEARCH FORM 
CLINICAL RESEARCH FORM 
The association between clinical manifestation, biochemical  markers ( Ca125), 
and diagnostic laparoscopy or laparotomy findings, with or without 
histopathological confirmation  for the diagnosis of endometriosis. 
Reg. No :  Age :  
Parity :  LCB :  
 
HISTORY TAKING 
Dysmenorrhoea 
 
 
 
 
 
 
 
 
 
 
 
 
Present                                                     Absent  
If dysmenorrhoea is present, please score the severity of pain according to 
the below criteria and take the sum to rank the severity: 
Score 0 1 2 3 
Limitation of 
ability to 
work 
Unaffected Rarely 
affected 
Moderately 
affected 
Clearly 
affected 
Co-existing 
of systemic 
symptoms 
Absent Present   
Need for 
analgesia 
No Yes   
Total score  
Rank of 
severity of 
pain 
Mild 
(1-2) 
Moderate 
 (3-4) 
Severe 
(5) 
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Deep 
dyspareunia 
 
 
 
 
 
Present                                                     Absent  
If deep dyspareunia is present, please score the severity of pain according 
to the below 10- point linear analogue scale: 
0 1 2 3 4 5 6 7 8 9 10 
 
No 
pain 
 Unbearable 
pain 
 
Pelvic pain  
 
Present                                                     Absent  
If pelvic pain is present, please score the severity of pain according to the 
below criteria and take the sum to rank the severity: 
Score 0 1 2 3 
Limitation of 
ability to 
work 
Unaffected Rarely 
affected 
Moderately 
affected 
Clearly 
affected 
Co-existing 
of systemic 
symptoms 
Absent Present   
Need for 
analgesia 
No Yes   
Total score  
Rank of 
severity of 
pain 
Mild 
(1-2) 
Moderate  
(3-4) 
Severe 
(5) 
 
 
Ovulation Pain 
 
 
 
 
 
Present                                                     Absent  
If ovulation pain is present, please score the severity of pain according to the 
below criteria and take the sum to rank the severity: 
Score 0 1 2 3 
Limitation of 
ability to 
work 
Unaffected Rarely 
affected 
Moderately 
affected 
Clearly 
affected 
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Co-existing 
of systemic 
symptoms 
Absent Present   
Need for 
analgesia 
No Yes   
Total score  
Rank of 
severity of 
pain 
Mild 
(1-2) 
Moderate  
(3-4) 
Severe 
(5) 
 
 
Non-menstrual 
Pain 
 
Present                                                     Absent  
If non-menstrual pain is present, please score the severity of pain 
according to the below criteria and take the sum to rank the severity: 
Score 0 1 2 3 
Limitation of 
ability to 
work 
Unaffected Rarely 
affected 
Moderately 
affected 
Clearly 
affected 
Co-existing 
of systemic 
symptoms 
Absent Present   
Need for 
analgesia 
No Yes   
Total score  
Rank of 
severity of 
pain 
Mild 
(1-2) 
Moderate  
(3-4) 
Severe 
(5) 
 
 
Dyschezia 
 
Present                                                     Absent  
If dyschezia is present, please score the severity of pain according to the 
below 10- point linear analogue scale: 
0 1 2 3 4 5 6 7 8 9 10 
No 
pain 
 Unbearable 
pain 
 
Sub- fertility Present                                                     Absent  
Duration: ………………  years 
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PHYSICAL EXAMINATION 
Height: ………… cm      Weight:  …………..kg 
Body mass index (BMI):  ……………kg/m2 
Abdominal examination: 
Abdominal 
mass 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Present                                                     Absent  
If abdominal mass is present, please evaluate the details of the mass as below: 
Size  
Site  
Margin 
 
 
Regular Irregular 
  
 
Surface 
 
 
Smooth Irregular 
  
 
Consistency 
 
 
Cystic Firm Hard 
   
 
Mobility 
 
 
Horizontal 
 
Mobile Restricted 
mobility 
Fixed 
Vertical Mobile Restricted 
mobility 
Fixed 
 
Tenderness 
 
 
Tender                                          Non- tender  
 
 
Pelvic examination: 
Vaginal 
nodule 
Present                                                     Absent  
If abdominal mass is present, please evaluate the details of the mass as below: 
Site  
Size  
Colour  
Tenderness Present                                            Absent  
 
 
Uterus 
 
 
 
 
Size   
Flexion Anteverted Retroverted 
Mobility Mobile Restricted Fixed 
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Adnexae 
 
 Right Left 
Cyst Present                  Absent   
If cyst is present, kindly 
evaluate as follows: 
Size  
Tenderness  
Margin  
Surface  
Consistency  
Mobility  
 
Present                 Absent   
If cyst is present, kindly 
evaluate as follows: 
Size  
Tenderness  
Margin  
Surface  
Consistency  
Mobility  
 
Ovary 
 
 
 
 
 
Size  
Tenderness  
Mobility  
 
 
Size  
Tenderness  
Mobility  
 
Uterosacral 
ligaments 
 
Thickened Not 
thickened 
Tender Non- tender 
 
Thickened Not 
thickened 
Tender Non- tender 
 
POD Normal            Obliterated Normal            Obliterated 
 
 
INVESTIGATIONS 
Ultrasound examination: 
Please circle the method of ultrasound used:                 TAS                                          TVS 
Ultrasound findings: 
Uterus: 
 Size  
Endometrial 
thickness 
 
Flexion  
Abnormality  
Ovaries: 
Right ovary Left ovary 
Size  Size  
Cyst Present            Absent Cyst Present            Absent 
 Size   Size  
 Locule Uniloculated/ 
Multiloculated 
 Locule Uniloculated/ 
Multiloculated 
 Septum Thin                 Thick  Septum Thin                 Thick 
 Papillary 
projection 
Present            Absent  Papillary 
projection 
Present            Absent 
 Nature Cystic     Solid cystic    
Solid 
 Nature Cystic     Solid cystic    
Solid 
 Content Clear   Thick with 
sediments   
 Content 
 
Clear   Thick with 
sediments   
 
Ca 125 :  
Date taken    :  
Level              :  
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OPERATIVE FINDINGS 
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STAGE OF ENDOMETRIOSIS:  STAGE I /  II/  III /  IV 
 
HISTOPATHOLOGICAL EXAMINATION (Please tick) 
CONFIRMED ENDOMETRIOSIS  
NO ENDOMETRIOSIS  
90 
 
APPENDIX 3 : CONSENT FORM 
PATIENT INFORMATION AND CONSENT FORM 
The  association  between clinical manifestation, biochemical marker (Ca125), 
and diagnostic laparoscopy or laparotomy findings with or without 
histopathological confirmation  for the diagnosis of endometriosis. 
  
Name of  Priciple  Researcher :   Dr Pang Suk Chin 
Name of  Supervisor  :    Assoc. Prof  Dr  Adibah Ibrahim 
Name of  co-supervisor (HUSM) :            Prof  Dr Mohd  Shukri  Othman 
                                                                       Dr Mohd. Pazudin Ismail 
                                                                       Dr. Wan Mohd. Zahiruddin Wan Mohd 
       
Name of Co-supervisor (KKM supervisor) :  Dr Haji Abdul Rahman 
                                                           Dr Nik Ahmad Nik Abdullah  
Introduction 
You are invited to take part voluntarily in a research study involving patient with the 
symptoms that suggestive of endometriosis. Before agreeing to participate in this 
research study, it is important that you read and understand this form. It describes the 
purpose, procedures, benefits, risks, discomforts, and precautions of the study. It also 
describes the alternative procedures available to you and your right to withdraw from 
the study at anytime.  If you participate, you will receive a copy of this form to keep for 
your records. 
Your participation in this study is expected to last for six months.  200 patients will be 
participating in this study. 
Purpose of the Study 
The purpose of this study is to develop the Cli-Endomet as a reliable tool in the 
diagnosis of endometriosis 
Qualification to Participate 
The doctor in charge of this study or a member of the study staff will discuss with you 
the requirements for participation in this study.  It is important that you are completely 
91 
 
truthful with the doctor and staff about your health history.  You should not participate in 
this study if you do not meet all the qualification criteria. 
To participate in this study you must be:  
 Consented to participate in the study 
 Age between 18 to 45 years  
 Having symptoms like chronic pelvic pain, dysmenorrhea, dyspareunia or 
infertility 
You cannot participate in this study if you are 
 known case of endometriosis which confirmed by tissue examination  
 diagnosed to have endometriosis and on treatment 
 refuse for operation for confirmation of the disease                 
 
Study Procedures 
You will only be invited to participate in this study if you fulfilled the above criteria.  
You will be first seen in the Gynaecology Clinic, whereby a few questions will be asked. 
You will be examined by the doctor and an ultrasound will be performed. Blood 
investigations will be taken, if you are having menses, blood investigation will be taken 
stat, if you are not having menses yet, you will be asked to come again for blood taking 
during menses. 
 You will be given the date for ward admission to undergo operation (which is not more 
than 3 months from your first day of follow up),the operation will be done by the 
specialists who are involved in this research. You may be allowed to be discharged 
after 3-5 days post-operatively if there are no complication. 
Risks 
There are general risks of operation. You might have minor side effect such as nausea, 
headache (3-5%), or major risks such as bleeding, internal organ injury (less than 3%). 
Participation in the Study 
Your participation in this study is entirely voluntary.  You may refuse to take part in the 
study or you may stop participating in the study at any time, without a penalty or loss of 
benefits to which you are otherwise entitled. 
Your participation also may be stopped by the study doctor without your consent.  
If you stop being part of this study, the study doctor or one of the staff members will talk 
to you about medical issues regarding the stopping of your participation. 
Possible Benefits 
Procedures will be provided at no cost to you.  You may receive information about your 
health from any physical examinations to be done in this study. In addition you will 
have your disease confirmed and appropriate treatment will be given to you. 
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Information obtained from this study will benefit Ministry of Health and future clinical 
approach of such problem. 
Questions 
If you have any question about this study or your rights, please contact: 
Dr Pang Suk Chin 
Jabatan Obstetrik & Ginekologi 
Hospital Raja Perempuan Zainab II 
Tel: 012-5114622 
 
If you have any questions Regarding the Ethical Approval, please contact: 
Puan Mazlita Zainal Abidin 
Setiausaha Jawatankuasa Etila Penyelidikan (Manusia) USM 
Pelantar Penyelidikan Sains Klinikal, USM Kampus Kesihatan 
Tel : 09-7672355 / 09-7672352 
 
Confidentiality 
Your medical information will be kept confidential by the study doctor and staff and will 
not be made publicly available unless disclosure is required by law. 
By signing this consent form, you authorize the record review, information 
storage and data transfer described above. 
Signatures 
To be entered into the study, you or a legal representative must sign the signature 
page.  
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Research Title : The  association  between clinical manifestation, biochemical 
marker (Ca125), and diagnostic laparoscopy or laparotomy findings with or 
without histopathological confirmation  for the diagnosis of endometriosis. 
  
Name of Principle Researcher: Dr Pang Suk Chin 
To become a part of this study, you or your legal representative must sign this page. 
 
By signing this page, I am confirming the followngs : 
I. I have read all of the information in this Patient Information and Consent Form 
including any information regarding the risks in this study and I have had 
time to think about it. 
II. All of my questions have been answered to my satisfaction. 
III. I voluntarily agree to be part of this research study to follow the study 
procedures, and to provide necessary information to the doctor, nurses, or other 
staff members, as requested. 
IV. I may freely choose to stop being a part of this study at anytime. 
V. I have received a copy of this Patient Information and Consent Form to keep for 
myself. 
 
……………………………………………. 
Patient’s name 
 
……………………………………………. 
Patient’s signature and contact no. 
 
……………………………………………. 
Patient’s signature or legal representative 
 
……………………………………………. 
Date (DD/MM/YY) 
 
……………………………………………. 
Witness name and signature 
 
……………………………………………. 
Date (DD/MM/YY) 
 
**All subjects / participants who are involved in this study will not be covered by 
insurance 
